A Phase 2 interventional study of PF-06651600 or Placebo and PF-06700841 or Placebo in Ulcerative Colitis, sponsored by Pfizer. Completed at 189 sites in 19 countries. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2022-07-21.
Sponsored by Pfizer · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 42 studies in Colitis, Ulcerative by Pfizer — 3 open to participants now, 7 under way, 2 of them phase 3. Colitis, Ulcerative · Pfizer.
Among the 42 studies in Colitis, Ulcerative by Pfizer, this one is the 8th largest by enrollment of the 24 interventional ones that give a count, is one of 3 that started in 2017, is one of 12 in phase 2, and was the 14th registered.
1,854 studies on the registry are indexed under Colitis, Ulcerative; 473 are open to participants now.
Browse Colitis, Ulcerative studies →3 of the 42 studies in Colitis, Ulcerative by Pfizer are open now, in 12 countries. Recruiting first, the newest first:
Pfizer · Sites in United States, Australia, Canada and 7 more countries
Ages 2–11
Pfizer · Sites in United States
Ages 18–64
Pfizer · Sites in United States, Japan, Poland and 2 more countries
Ages 12–17
By country, each count listing its studies:
Of the 307 Colitis, Ulcerative studies recruiting now, 134 (44%) set no upper age limit and 136 (44%) stop at 75 or younger; 71 take children under 18; 41 take healthy volunteers.
This study: 18 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
42 studies; the count open now beside each. This study's row is marked.
First in 2005; this study’s year is marked. 3 started in 2017.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 319 is above the median of 70 across 1,237 interventional studies indexed under Colitis, Ulcerative.
Median enrollment 129 across the 24 interventional studies, 276 across the 16 observational. Of the 32 that completed or were terminated, 26 (81%) have results posted.
This tab as a report to print or save as PDF → With an account.
Pfizer is the lead sponsor of 3,337 studies on the registry; 150 are open to participants now.
Of its 601 completed or terminated interventional studies of FDA-regulated products, 392 (65%) have results posted.
3 of the studies in Colitis, Ulcerative by Pfizer that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04624230Phase 3PfizerEvaluation of Oral Tofacitinib in Children Aged 2 to 17 Years Old Suffering From Moderate to Severe Ulcerative Colitis | 2027-03-17 |
| NCT06294925PfizerA Study to Learn About the Effectiveness of Etrasimod in People With Ulcerative Colitis | 2027-05-13 |
| NCT06398626PfizerAn Observational Study of Etrasimod in Adult Patients With Moderate to Severe Ulcerative Colitis | 2027-10-01 |
Add all 3 to your calendar (.ics) → With an account.
Among the 42 studies in Colitis, Ulcerative by Pfizer, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to determine whether PF-06651600 and PF-06700841 are effective in treatment of moderate to severe ulcerative colitis.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Delivered orally for 8 weeks
Drug: PF-06651600 or Placebo
Delivered orally for 8 weeks
Drug: PF-06651600 or Placebo
Delivered orally for 8 weeks.
Drug: PF-06651600 or Placebo
Delivered orally for 8 weeks.
Drug: PF-06651600 or Placebo
Delivered orally for 8 weeks
Drug: PF-06700841 or Placebo
Delivered orally for 8 weeks.
Drug: PF-06700841 or Placebo
Delivered orally for 8 weeks.
Drug: PF-06700841 or Placebo
Delivered orally for 8 weeks.
Drug: PF-06700841 or Placebo
Delivered orally for 24 weeks.
Drug: PF-06651600
Delivered orally for 24 weeks.
Drug: PF-06700841
Delivered orally for 8 weeks.
Delivered orally for 8 weeks.
Delivered orally for 24 weeks.
Delivered orally for 24 weeks.
Total Mayo Score at Week 8 (Induction Period)
The Mayo score is a tool designed to measure disease activity for ulcerative colitis. The Mayo scoring system ranges from 0 to 12 points and consists of 4 subscores, which are stool frequency, rectal bleeding, findings on endoscopy and physician's global assessment. Each subscore graded 0 to 3 with the higher score indicates more severe disease activity and lower score denotes improvement of disease activity as measured by the total Mayo score.
Time frame: Week 8
Number of Participants With AEs, SAEs and Discontinuation Due to AEs (Chronic Period)
An AE was an untoward medical occurrence in a participant who received study treatment without regard to possibility of causal relationship. An SAE was an AE resulting in any of the following outcomes: death, life-threatening experience, initial or prolonged inpatient hospitalization, persistent or significant disability/incapacity, congenital anomaly/birth defect. Treatment-emergent AEs were those with initial onset or that worsen in severity after the first dose of study medication. All AEs mentioned below are treatment-emergent AEs.
Time frame: From Week 8 up to Week 32
Number of Participants With Laboratory Test Abnormalities (Chronic Period)
The number of participants with a laboratory abnormality meeting the pre-specified criteria defined in the study protocol while on study treatment or during lag time are reported here. Baseline is defined as the last measurement prior to receiving study treatment. Laboratory data included hematology test, serum chemistry test, C-creative protein and viral surveillance.
Time frame: From Week 8 to Week 32
Number of Participants With Laboratory Test Abnormalities-hematology (Chronic Period)
The number of participants with a laboratory abnormality meeting specified criteria while on study treatment or during lag time are reported here. Baseline is defined as the last measurement prior to receiving study treatment. The list of hematology test parameters were as follows: hemoglobin, hematocrit, red blood cell count, platelet count, white blood cell count, total neutrophils (absolute, Abs), eosinophils (Abs), monocytes (Abs), basophils (Abs), lymphocytes (Abs), prothrombin time (PT)/international normalized ratio (INR)/partial thromboplastin time (PTT), and reticulocytes (% and Abs). Percentages are displayed for the laboratory tests having a category with greater or equal to 1 evaluable participant.
Time frame: From Week 8 to Week 32
Number of Participants With Abnormal Vital Signs Data (Chronic Period)
The vital signs data included the single sitting blood pressure, pulse rate and temperature. The criteria of vital sign abnormality are indicated below.
Time frame: From Week 8 to Week 32
Number of Participants With Abnormal ECG Findings (Chronic Period)
The number of participants with abnormal ECG findings during the chronic period (from Week 9 to Week 32) are reported below.
Time frame: Week 8 to Week 32
Number of Participants With Serious Infections (Chronic Period)
Serious infections was defined as any infection (for example, viral, bacterial, and fungal) requiring hospitalization or parenteral antimicrobials.
Time frame: Week 8 to Week 32
Number of Participants With Laboratory Test Abnormalities-clinical Chemistry (Chronic Period)
The number of participants with a laboratory abnormality meeting specified criteria while on study treatment or during lag time are reported here. Baseline is defined as the last measurement prior to receiving study treatment. The list of serum chemistry test parameters were as follows: blood urea nitrogen, creatinine, cystatin C, glucose, calcium, sodium, potassium, gamma glutamyl transferase, chloride, aspartate aminotransferase (AST), alanine aminotransferase (ALT), total bilirubin, direct bilirubin, alkaline phosphatase, uric acid, albumin, total protein, creatine kinase (CK), total cholesterol, triglycerides, high-density lipoproteins (HDL), and low-density lipoprotein (LDL).
Time frame: Week 8 to Week 32
Number of Participants With Laboratory Test Abnormalities-urinalysis (Chronic Period)
The number of participants with a laboratory abnormality meeting specified criteria while on study treatment or during lag time are reported here. Baseline is defined as the last measurement prior to receiving study treatment. The list of urinalysis test parameters were as follows:pH, glucose (qual), protein (qual), blood (qual), ketones, nitrites, leukocyte esterase, microscopy, and spot urine albumin/creatinine ratio. The criteria of laboratory abnormality is defined as one of the following conditions was met: 1)associated with accompanying symptoms;2)Test result requires additional diagnostic testing or medical/surgical intervention;3)Test result leads to a change in study dosing (outside of any protocol specified dose adjustments) or discontinuation from the study, significant additional concomitant drug treatment, or other therapy;4)Test result is considered to be an AE by the investigator or sponsor.
Time frame: Week 8 to Week 32
Number of Participants With Adverse Events (AEs), Serious Adverse Events (SAEs) and Discontinuation Due to AEs (All-causalities) (Induction Period)
An AE was an untoward medical occurrence in a participant who received study treatment without regard to possibility of causal relationship. An SAE was an AE resulting in any of the following outcomes: death, life-threatening experience, initial or prolonged inpatient hospitalization, persistent or significant disability/incapacity, congenital anomaly/birth defect. Treatment-emergent AEs were those with initial onset or that worsen in severity after the first dose of study medication. All AEs mentioned below are treatment-emergent AEs.
Time frame: From Day 1 up to Week 8
Number of Participants With Laboratory Test Abnormalities (Induction Period)
The number of participants with a laboratory abnormality meeting the pre-specified criteria defined in the study protocol while on study treatment or during lag time are reported here. Baseline is defined as the last measurement prior to receiving study treatment. Laboratory data included hematology test, serum chemistry test, C-creative protein and viral surveillance. The criteria of laboratory abnormality is defined as one of the following conditions was met: 1)associated with accompanying symptoms;2)Test result requires additional diagnostic testing or medical/surgical intervention;3)Test result leads to a change in study dosing (outside of any protocol specified dose adjustments) or discontinuation from the study, significant additional concomitant drug treatment, or other therapy;4)Test result is considered to be an AE by the investigator or sponsor.
Time frame: From Day 1 up to Week 8
Number of Participants With Laboratory Test Abnormalities-hematology (Induction Period)
The number of participants with a laboratory abnormality meeting specified criteria while on study treatment or during lag time are reported here. Baseline is defined as the last measurement prior to receiving study treatment. The list of hematology test parameters were as follows: hemoglobin, hematocrit, red blood cell count, platelet count, white blood cell count, total neutrophils (absolute, Abs), eosinophils (Abs), monocytes (Abs), basophils (Abs), lymphocytes (Abs), prothrombin time (PT)/international normalized ratio (INR)/partial thromboplastin time (PTT), and reticulocytes (% and Abs). Percentages are displayed for the laboratory tests having a category with greater or equal to 1 evaluable participant.
Time frame: From Day 1 up to Week 8
Number of Participants With Laboratory Test Abnormalities-clinical Chemistry (Induction Period)
The number of participants with a laboratory abnormality meeting specified criteria while on study treatment or during lag time are reported here. Baseline is defined as the last measurement prior to receiving study treatment. The list of serum chemistry test parameters were as follows: blood urea nitrogen, creatinine, cystatin C, glucose, calcium, sodium, potassium, gamma glutamyl transferase, chloride, aspartate aminotransferase (AST), alanine aminotransferase (ALT), total bilirubin, direct bilirubin, alkaline phosphatase, uric acid, albumin, total protein, creatine kinase (CK), total cholesterol, triglycerides, high-density lipoproteins (HDL), and low-density lipoprotein (LDL)
Time frame: From Day 1 up to Week 8
Number of Participants With Laboratory Test Abnormalities- Urinalysis (Induction Period)
The number of participants with a laboratory abnormality meeting specified criteria while on study treatment or during lag time are reported here. Baseline is defined as the last measurement prior to receiving study treatment. The list of urinalysis test parameters were as follows:pH, glucose (qual), protein (qual), blood (qual), ketones, nitrites, leukocyte esterase, microscopy, and spot urine albumin/creatinine ratio. The criteria of laboratory abnormality is defined as one of the following conditions was met: 1)associated with accompanying symptoms;2)Test result requires additional diagnostic testing or medical/surgical intervention;3)Test result leads to a change in study dosing (outside of any protocol specified dose adjustments) or discontinuation from the study, significant additional concomitant drug treatment, or other therapy;4)Test result is considered to be an AE by the investigator or sponsor.
Time frame: From Day 1 up to Week 8
Number of Participants With Abnormal Vital Signs Data (Induction Period)
The vital signs data included the single sitting blood pressure, pulse rate and temperature. The criteria of vital sign abnormality are indicated below.
Time frame: From screening to Week 8
Number of Participants With Abnormal Electrocardiogram (ECG) Findings (Induction Period)
The number of participants with abnormal ECG findings during the induction period (from Day 1 to Week 8) are reported below. The criteria of test abnormality is defined as one of the following conditions was met: 1)associated with accompanying symptoms;2)Test result requires additional diagnostic testing or medical/surgical intervention;3)Test result leads to a change in study dosing (outside of any protocol specified dose adjustments) or discontinuation from the study, significant additional concomitant drug treatment, or other therapy;4)Test result is considered to be an AE by the investigator or sponsor.
Time frame: From screening to Week 8
Number of Participants With Serious Infections (Induction Period)
Serious infections was defined as any infection (for example, viral, bacterial, and fungal) requiring hospitalization or parenteral antimicrobials including Listeria encephalitis, Pneumonia, Viral infection.
Time frame: From Day 1 up to Week 8
Percentage of Participants Achieving Remission Based on Total Mayo Score at Week 8 (Induction Period)
The Mayo Score is a tool designed to measure disease activity for ulcerative colitis. The Mayo scoring system ranges from 0 to 12 points and consists of 4 subscores, which are stool frequency, rectal bleeding, findings on endoscopy and physician's global assessment. Each subscore graded 0 to 3 with the higher score indicating more severe disease activity. Clinical remission was defined as total Mayo score of 2 points or lower, with no individual subscore exceeding 1 point and a rectal bleeding subscore of 0.
Time frame: Week 8
Percentage of Participants Achieving Improvement in Endoscopic Appearance Based on Total Mayo Score at Week 8 (Induction Period)
The Mayo Score is a tool designed to measure disease activity for ulcerative colitis. The Mayo scoring system ranges from 0 to 12 points and consists of 4 subscores, which are stool frequency, rectal bleeding, findings on endoscopy and physician's global assessment. Each subscore graded 0 to 3 with the higher score indicating more severe disease activity. Improvement in endoscopic subscore appearance was defined at Mayo endoscopic subscore of ≤1.
Time frame: Week 8
Percentage of Participants Achieving Clinical Response Based on Total Mayo Score at Week 8 (Induction Period)
The Mayo Score is a tool designed to measure disease activity for ulcerative colitis. The Mayo scoring system ranges from 0 to 12 points and consists of 4 subscores, which are stool frequency, rectal bleeding, findings on endoscopy and physician's global assessment. Each subscore graded 0 to 3 with the higher score indicating more severe disease activity. Clinical response was defined as decrease from baseline in total Mayo score of at least 3 points and at least 30%, with an accompanying decrease in the subscore for rectal bleeding of at least 1 point or absolute subscore for rectal bleeding of 0 or 1.
Time frame: Week 8
Percentage of Participants Achieving Endoscopic Remission Based on Total Mayo Score at Week 8 (Induction Period)
The Mayo Score is a tool designed to measure disease activity for ulcerative colitis. The Mayo scoring system ranges from 0 to 12 points and consists of 4 subscores, which are stool frequency, rectal bleeding, findings on endoscopy and physician's global assessment. Each subscore graded 0 to 3 with the higher score indicating more severe disease activity. Endoscopic remission was defined as endoscopic subscore of 0.
Time frame: Week 8
Percentage of Participants Achieving Symptomatic Remission Based on Total Mayo Score at Week 8 (Induction Period)
The Mayo Score is a tool designed to measure disease activity for ulcerative colitis. The Mayo scoring system ranges from 0 to 12 points and consists of 4 subscores, which are stool frequency, rectal bleeding, findings on endoscopy and physician's global assessment. Each subscore graded 0 to 3 with the higher score indicating more severe disease activity. Symptomatic remission was defined as total Mayo score of 2 points or lower, with no individual subscore exceeding 1 point, and both rectal bleeding and stool frequency subscores of 0.
Time frame: Week 8
Percentage of Participants Achieving Deep Remission Based on Total Mayo Score at Week 8 (Induction Period)
The Mayo Score is a tool designed to measure disease activity for ulcerative colitis. The Mayo scoring system ranges from 0 to 12 points and consists of 4 subscores, which are stool frequency, rectal bleeding, findings on endoscopy and physician's global assessment. Each subscore graded 0 to 3 with the higher score indicating more severe disease activity. Deep remission was defined as total Mayo score of 2 points or lower, with no individual subscore exceeding 1 point and a zero on both endoscopic and rectal bleeding subscore.
Time frame: Week 8
Partial Mayo Score and Change From Baseline at Weeks 2, 4 and 8 (Induction Period)
The Mayo Score is a tool designed to measure disease activity for ulcerative colitis. The Mayo scoring system ranges from 0 to 12 points and consists of 4 subscores, which are stool frequency, rectal bleeding, findings on endoscopy and physician's global assessment. Each subscore graded 0 to 3 with the higher score indicating more severe disease activity. The partial Mayo score does not incorporate the endoscopy score and the partial Mayo score ranges from 0 to 9.
Time frame: Baseline, Weeks 2, 4 and 8
Change From Baseline in Total Mayo Score at Week 8 (Induction Period)
The Mayo Score is a tool designed to measure disease activity for ulcerative colitis. The Mayo scoring system ranges from 0 to 12 points and consists of 4 subscores, which are stool frequency, rectal bleeding, findings on endoscopy and physician's global assessment. Each subscore graded 0 to 3 with the higher score indicating more severe disease activity.
Time frame: Baseline, Week 8
Inflammatory Bowel Disease Questionnaire (IBDQ) Domain Score and Total Score at Weeks 4 and 8 (Induction Period)
IBDQ is a psychometrically validated patient reported outcome (PRO) instrument for measuring the disease specific quality of life in participants with inflammatory bowel disease (IBD). The IBDQ is comprised of 32 items, which are grouped into 4 dimensions: bowel function, emotional status, systemic symptoms and social function. The 4 domains are scored as follows: Bowel symptoms: 10 to 70; Systemic symptoms: 5 to 35.; Emotional function: 12 to 84; Social function: 5 to 35. The total IBDQ score ranges from 32 to 224. For the total score and each domain, a higher score indicates better quality of life.
Time frame: Week 4 and Week 8
Change From Baseline in IBDQ Total Score at Weeks 4 and 8 (Induction Period)
IBDQ is a psychometrically validated PRO instrument for measuring the disease specific quality of life in participants with IBD. The IBDQ is comprised of 32 items, which are grouped into 4 dimensions: bowel function, emotional status, systemic symptoms and social function. The 4 domains are scored as follows: Bowel symptoms: 10 to 70; Systemic symptoms: 5 to 35.; Emotional function: 12 to 84; Social function: 5 to 35. The total IBDQ score ranges from 32 to 224. For the total score and each domain, a higher score indicates better quality of life. Baseline value is defined as the last non-missing measurement collected prior to or on Day 1.
Time frame: Baseline, Weeks 4 and 8
Percentage of Participants With IBDQ Total Score Greater Than or Equal to 170 at Weeks 4 and 8 (Induction Period)
IBDQ is a psychometrically validated PRO instrument for measuring the disease specific quality of life in participants with IBD. The IBDQ is comprised of 32 items, which are grouped into 4 dimensions: bowel function, emotional status, systemic symptoms and social function. The 4 domains are scored as follows: Bowel symptoms: 10 to 70; Systemic symptoms: 5 to 35.; Emotional function: 12 to 84; Social function: 5 to 35. The total IBDQ score ranges from 32 to 224. For the total score and each domain, a higher score indicates better quality of life.
Time frame: Week 4 and Week 8
Percentage of Participants With Greater Than or Equal to 16 Points Increase in IBDQ Total Score From Baseline at Weeks 4 and 8 (Induction Period)
IBDQ is a psychometrically validated PRO instrument for measuring the disease specific quality of life in participants with IBD. The IBDQ is comprised of 32 items, which are grouped into 4 dimensions: bowel function, emotional status, systemic symptoms and social function. The 4 domains are scored as follows: Bowel symptoms: 10 to 70; Systemic symptoms: 5 to 35.; Emotional function: 12 to 84; Social function: 5 to 35. The total IBDQ score ranges from 32 to 224. For the total score and each domain, a higher score indicates better quality of life.
Time frame: Baseline, Week 4 and 8
Percentage of Participants With Improvement in IBDQ Bowel Symptom Domain at Weeks 4 and 8 (Induction Period)
IBDQ is a psychometrically validated PRO instrument for measuring the disease specific quality of life in participants with IBD. The IBDQ is comprised of 32 items, which are grouped into 4 dimensions: bowel function, emotional status, systemic symptoms and social function. The 4 domains are scored as follows: Bowel symptoms: 10 to 70; Systemic symptoms: 5 to 35.; Emotional function: 12 to 84; Social function: 5 to 35. The total IBDQ score ranges from 32 to 224. For the total score and each domain, a higher score indicates better quality of life. The improvement in IBDQ bowel symptom domain was defined as an increase of ≥1.2 points from baseline in average score among bowel symptoms domain (items 1, 5, 9, 13, 17, 20, 22, 24, 26, 29).
Time frame: Week 4 and Week 8
Change From Baseline in Short Form 36 Version 2 (SF-36v2) Acute Mental Component Summary (MCS) Score and Physical Component Summary (PCS) Score at Weeks 4 and 8 (Induction Period)
The SF-36 version 2 (Acute version) is a 36-item generic health status measure. It measures 8 general health concepts or domains: Physical Functioning (PF), Role-Physical (RP), Bodily Pain (BP), General Health (GH), Vitality (VT), Social Functioning (SF), Role-Emotional (RE), and Mental Health (MH). These 8 domains can also be summarized as physical and mental component scores. The summary component scores, Physical Component Summary (PCS) and Mental Component Summary (MCS), are based on a normalized sum of the 8 scale scores PF, RP, BP, GH, VT, SF, RE, and MH . All domains and summary components are scored such that a higher score indicates a higher functioning or health level. The minimum and maximum scores of the PCS Score are 6.1 and 79.7, respectively. The minimum and maximum scores of the MCS Score are -3.8 and 78.7, respectively.
Time frame: Week 4 and Week 8
Change From Baseline in Euro Quality of Life Questionnaire 5 Dimensions 3 Levels (EQ-5D 3L) Utility Score and EQ-5D Visual Analog Scale (VAS) at Weeks 4 and 8 (Induction Period)
For EQ-5D 3L, participant rated questionnaire to assess generic health status in two parts: single utility score and visual analog scale. For utility score, participants rated their current health state on 5 dimensions: mobility, self-care, usual activities, pain and discomfort, and anxiety and depression with each dimension having three levels of function: 1 indicates no problem; 2 indicates some problem; 3 indicates extreme problem. Scoring formula developed by EuroQol Group assigns a utility value for each domain in the profile. Score was transformed and results in a total score range of 0.05 to 1.00; higher scores indicating a better health state. The EQ-5D VAS records the respondent's self rated health on a scale from 0 (worst imaginable health state) to 100 (best imaginable health state).
Time frame: Week 4 and Week 8
Total Mayo Score at Week 32 (Chronic Period)
The Mayo Score is a tool designed to measure disease activity for ulcerative colitis. The Mayo scoring system ranges from 0 to 12 points and consists of 4 subscores, which are stool frequency, rectal bleeding, findings on endoscopy and physician's global assessment. Each subscore graded 0 to 3 with the higher score indicating more severe disease activity.
Time frame: Week 32
Percentage of Participants Achieving Remission Based on Total Mayo Score at Week 32 (Chronic Period)
The Mayo Score is a tool designed to measure disease activity for ulcerative colitis. The Mayo scoring system ranges from 0 to 12 points and consists of 4 subscores, which are stool frequency, rectal bleeding, findings on endoscopy and physician's global assessment. Each subscore graded 0 to 3 with the higher score indicating more severe disease activity. Clinical remission was defined as total Mayo score of 2 points or lower, with no individual subscore exceeding 1 point and a rectal bleeding subscore of 0.
Time frame: Week 32
Percentage of Participants Achieving Improvement in Endoscopic Appearance Based on Mayo Score at Week 32 (Chronic Period)
The Mayo Score is a tool designed to measure disease activity for ulcerative colitis. The Mayo scoring system ranges from 0 to 12 points and consists of 4 subscores, which are stool frequency, rectal bleeding, findings on endoscopy and physician's global assessment. Each subscore graded 0 to 3 with the higher score indicating more severe disease activity. Improvement in endoscopic appearance was defined at Mayo endoscopic subscore of ≤1.
Time frame: Week 32
Change From Baseline in Total Mayo Score at Week 32 (Chronic Period)
The Mayo Score is a tool designed to measure disease activity for ulcerative colitis. The Mayo scoring system ranges from 0 to 12 points and consists of 4 subscores, which are stool frequency, rectal bleeding, findings on endoscopy and physician's global assessment. Each subscore graded 0 to 3 with the higher score indicating more severe disease activity.
Time frame: Week 32
The study consisted of a screening period of up to 6 weeks, an 8-week double-blind induction period, and an additional 24-week open-label active chronic dosing period followed by a 4-week follow up period after the last dose of investigational product.
| Milestone | Placebo (Induction) | PF-06651600 20 mg (Induction) | PF-06651600 70 mg (Induction) | PF-06651600 200 mg (Induction) | PF-06700841 10 mg (Induction) | PF-06700841 30 mg (Induction) | PF-06700841 60 mg (Induction) | PF-06651600 200 mg -> PF-06651600 50 mg | PF-06651600 70 mg -> PF-06651600 50 mg | PF-06651600 20 mg -> PF-06651600 50 mg | Placebo -> PF-06651600 50 mg | PF-06700841 60 mg -> PF-06700841 30 mg | PF-06700841 30 mg -> PF-06700841 30 mg | PF-06700841 10 mg -> PF-06700841 30 mg | Placebo -> PF-06700841 30 mg | Pooling Placebo During Chronic |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Started | 25 | 51 | 49 | 50 | 48 | 47 | 47 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Completed | 21 | 44 | 43 | 41 | 45 | 43 | 44 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Not completed | 4 | 7 | 6 | 9 | 3 | 4 | 3 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Adverse event | 0 | 4 | 0 | 5 | 1 | 2 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Death | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Physician decision | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Withdrawal by subject | 2 | 0 | 3 | 1 | 1 | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: No longer meeting eligibility criteria | 0 | 0 | 0 | 1 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Protocol violation | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Lack of efficacy | 1 | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Other | 0 | 0 | 1 | 2 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Lost to follow-up | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Milestone | Placebo (Induction) | PF-06651600 20 mg (Induction) | PF-06651600 70 mg (Induction) | PF-06651600 200 mg (Induction) | PF-06700841 10 mg (Induction) | PF-06700841 30 mg (Induction) | PF-06700841 60 mg (Induction) | PF-06651600 200 mg -> PF-06651600 50 mg | PF-06651600 70 mg -> PF-06651600 50 mg | PF-06651600 20 mg -> PF-06651600 50 mg | Placebo -> PF-06651600 50 mg | PF-06700841 60 mg -> PF-06700841 30 mg | PF-06700841 30 mg -> PF-06700841 30 mg | PF-06700841 10 mg -> PF-06700841 30 mg | Placebo -> PF-06700841 30 mg | Pooling Placebo During Chronic |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Started | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 35 | 36 | 39 | 10 | 38 | 37 | 39 | 9 | 37 |
| Completed | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 33 | 33 | 33 | 10 | 31 | 26 | 31 | 5 | 20 |
| Not completed | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2 | 3 | 6 | 0 | 7 | 11 | 8 | 4 | 17 |
| Withdrew: Adverse event | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 2 | 0 | 1 | 4 | 1 | 1 | 5 |
| Withdrew: Lack of efficacy | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2 | 1 | 0 | 5 | 0 | 2 | 0 | 8 |
| Withdrew: Pregnancy | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 1 |
| Withdrew: Withdrawal by subject | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 6 | 3 | 3 | 2 |
| Withdrew: Other | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 1 | 0 | 0 | 1 | 0 | 0 | 1 |
| Withdrew: Non-compliance with study drug | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 |
| Withdrew: Protocol violation | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 |
| Withdrew: No longer meeting eligibility criteria | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 |
The Mayo score is a tool designed to measure disease activity for ulcerative colitis. The Mayo scoring system ranges from 0 to 12 points and consists of 4 subscores, which are stool frequency, rectal bleeding, findings on endoscopy and physician's global assessment. Each subscore graded 0 to 3 with the higher score indicates more severe disease activity and lower score denotes improvement of disease activity as measured by the total Mayo score.
| Units on a scale | Placebo (Induction) | PF-06651600 20 mg (Induction) | PF-06651600 70 mg (Induction) | PF-06651600 200 mg (Induction) | PF-06700841 10 mg (Induction) | PF-06700841 30 mg (Induction) | PF-06700841 60 mg (Induction) |
|---|---|---|---|---|---|---|---|
| Total Mayo Score at Week 8 (Induction Period) | 7.88 (6.95 to 8.81) | 5.85 (5.18 to 6.51) | 4.00 (3.33 to 4.67) | 3.27 (2.58 to 3.96) | 6.08 (5.43 to 6.74) | 5.60 (4.93 to 6.27) | 4.67 (4.01 to 5.33) |
An AE was an untoward medical occurrence in a participant who received study treatment without regard to possibility of causal relationship. An SAE was an AE resulting in any of the following outcomes: death, life-threatening experience, initial or prolonged inpatient hospitalization, persistent or significant disability/incapacity, congenital anomaly/birth defect. Treatment-emergent AEs were those with initial onset or that worsen in severity after the first dose of study medication. All AEs mentioned below are treatment-emergent AEs.
| Participants | PF-06651600 200 mg -> PF-06651600 50 mg | PF-06651600 70 mg -> PF-06651600 50 mg | PF-06651600 20 mg -> PF-06651600 50 mg | Placebo -> PF-06651600 50 mg | PF-06700841 60 mg -> PF-06700841 30 mg | PF-06700841 30 mg -> PF-06700841 30 mg | PF-06700841 10 mg -> PF-06700841 30 mg | Placebo -> PF-06700841 30 mg | Pooling Placebo During Chronic |
|---|---|---|---|---|---|---|---|---|---|
| Participants with AEs | 18 | 27 | 18 | 8 | 21 | 23 | 26 | 4 | 18 |
| Participants with SAEs | 3 | 1 | 1 | 0 | 2 | 4 | 2 | 0 | 0 |
| Participants discontinued from study due to AEs | 1 | 1 | 3 | 1 | 1 | 4 | 1 | 1 | 6 |
The number of participants with a laboratory abnormality meeting the pre-specified criteria defined in the study protocol while on study treatment or during lag time are reported here. Baseline is defined as the last measurement prior to receiving study treatment. Laboratory data included hematology test, serum chemistry test, C-creative protein and viral surveillance.
| Participants | PF-06651600 200 mg -> PF-06651600 50 mg | PF-06651600 70 mg -> PF-06651600 50 mg | PF-06651600 20 mg -> PF-06651600 50 mg | Placebo -> PF-06651600 50 mg | PF-06700841 60 mg -> PF-06700841 30 mg | PF-06700841 30 mg -> PF-06700841 30 mg | PF-06700841 10 mg -> PF-06700841 30 mg | Placebo -> PF-06700841 30 mg | Pooling Placebo During Chronic |
|---|---|---|---|---|---|---|---|---|---|
| Number of Participants With Laboratory Test Abnormalities (Chronic Period) | 27 | 31 | 33 | 8 | 29 | 27 | 28 | 8 | 23 |
The number of participants with a laboratory abnormality meeting specified criteria while on study treatment or during lag time are reported here. Baseline is defined as the last measurement prior to receiving study treatment. The list of hematology test parameters were as follows: hemoglobin, hematocrit, red blood cell count, platelet count, white blood cell count, total neutrophils (absolute, Abs), eosinophils (Abs), monocytes (Abs), basophils (Abs), lymphocytes (Abs), prothrombin time (PT)/international normalized ratio (INR)/partial thromboplastin time (PTT), and reticulocytes (% and Abs). Percentages are displayed for the laboratory tests having a category with greater or equal to 1 evaluable participant.
| Participants | PF-06651600 200 mg -> PF-06651600 50 mg | PF-06651600 70 mg -> PF-06651600 50 mg | PF-06651600 20 mg -> PF-06651600 50 mg | Placebo -> PF-06651600 50 mg | PF-06700841 60 mg -> PF-06700841 30 mg | PF-06700841 30 mg -> PF-06700841 30 mg | PF-06700841 10 mg -> PF-06700841 30 mg | Placebo -> PF-06700841 30 mg | Pooling Placebo During Chronic |
|---|---|---|---|---|---|---|---|---|---|
| Hemoglobin (g/dL) <0.8× LLN | 2 | 2 | 1 | 1 | 3 | 3 | 6 | 2 | 3 |
| Hematocrit (%) <0.8× LLN | 0 | 2 | 1 | 0 | 1 | 1 | 1 | 1 | 2 |
| Erythrocytes (10^6/mm^3) <0.8× LLN | 0 | 1 | 1 | 0 | 1 | 0 | 1 | 1 | 1 |
| Reticulocytes (Abs) (10^3/mm^3) >1.5× ULN | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 |
| Erythrocytes Mean Corpuscular Volume (10^-15L) <0.9× LLN | 0 | 0 | 1 | 0 | 0 | 1 | 0 | 0 | 0 |
| Platelets (10^3/mm^3) >1.75× ULN | 0 | 0 | 0 | 0 | 3 | 1 | 2 | 0 | 2 |
| Reticulocytes/Erythrocytes (%) >1.5× ULN | 1 | 1 | 2 | 0 | 1 | 1 | 0 | 0 | 1 |
| Leukocytes (10^3/mm^3) >1.5× ULN | 0 | 0 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| Lymphocytes (Abs) (10^3/mm^3) <0.8× LLN | 7 | 6 | 6 | 1 | 0 | 0 | 3 | 0 | 3 |
| Lymphocytes (Abs) (10^3/mm^3) >1.2× ULN | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 |
| Neutrophils (Abs) (10^3/mm^3) <0.8× LLN | 1 | 2 | 0 | 0 | 3 | 1 | 2 | 1 | 1 |
| Neutrophils (Abs) (10^3/mm^3) >1.2× ULN | 3 | 8 | 11 | 1 | 8 | 6 | 6 | 3 | 6 |
| Basophils (Abs) (10^3/mm^3) >1.2× ULN | 0 | 0 | 0 | 0 | 2 | 1 | 0 | 0 | 1 |
| Eosinophils (Abs) (10^3/mm^3) >1.2x ULN | 0 | 0 | 0 | 0 | 2 | 1 | 0 | 0 | 2 |
| Monocytes (Abs) (10^3/mm^3) >1.2× ULN | 0 | 0 | 0 | 0 | 2 | 2 | 0 | 0 | 0 |
| Activated PTT (second) >1.1× ULN | 0 | 3 | 1 | 0 | 2 | 0 | 0 | 0 | 0 |
| PT (second) >1.1× ULN | 2 | 3 | 2 | 0 | 2 | 2 | 0 | 0 | 0 |
| Prothrombin INR >1.1× ULN | 2 | 3 | 2 | 0 | 2 | 1 | 0 | 0 | 0 |
The vital signs data included the single sitting blood pressure, pulse rate and temperature. The criteria of vital sign abnormality are indicated below.
| Participants | PF-06651600 200 mg -> PF-06651600 50 mg | PF-06651600 70 mg -> PF-06651600 50 mg | PF-06651600 20 mg -> PF-06651600 50 mg | Placebo -> PF-06651600 50 mg | PF-06700841 60 mg -> PF-06700841 30 mg | PF-06700841 30 mg -> PF-06700841 30 mg | PF-06700841 10 mg -> PF-06700841 30 mg | Placebo -> PF-06700841 30 mg | Pooling Placebo During Chronic |
|---|---|---|---|---|---|---|---|---|---|
| Sitting Systolic Blood Pressure Value <90 mmHg | 0 | 0 | 1 | 0 | 0 | 0 | 1 | 0 | 1 |
| Sitting Systolic Blood Pressure Change ≥30 mmHg Increase | 0 | 3 | 4 | 0 | 3 | 2 | 3 | 0 | 3 |
| Sitting Systolic Blood Pressure Change ≥30 mmHg Decrease | 0 | 0 | 0 | 0 | 1 | 1 | 0 | 0 | 1 |
| Sitting Diastolic Blood Pressure Value <50 mmHg | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Sitting Diastolic Blood Pressure Change ≥20 mmHg Increase | 0 | 1 | 6 | 1 | 4 | 2 | 1 | 1 | 1 |
| Sitting Diastolic Blood Pressure Change ≥20 mmHg Decrease | 2 | 4 | 5 | 0 | 2 | 3 | 1 | 0 | 2 |
| Sitting Pulse Rate Value <40 beat per minute (bpm) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Sitting Pulse Rate Value >120 bpm | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 |
The number of participants with abnormal ECG findings during the chronic period (from Week 9 to Week 32) are reported below.
| Participants | PF-06651600 200 mg -> PF-06651600 50 mg | PF-06651600 70 mg -> PF-06651600 50 mg | PF-06651600 20 mg -> PF-06651600 50 mg | Placebo -> PF-06651600 50 mg | PF-06700841 60 mg -> PF-06700841 30 mg | PF-06700841 30 mg -> PF-06700841 30 mg | PF-06700841 10 mg -> PF-06700841 30 mg | Placebo -> PF-06700841 30 mg | Pooling Placebo During Chronic |
|---|---|---|---|---|---|---|---|---|---|
| Abnormal, not clinically significant | 3 | 6 | 2 | 1 | 1 | 2 | 4 | 2 | 4 |
| Abnormal, clinically significant | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Serious infections was defined as any infection (for example, viral, bacterial, and fungal) requiring hospitalization or parenteral antimicrobials.
| Participants | PF-06651600 200 mg -> PF-06651600 50 mg | PF-06651600 70 mg -> PF-06651600 50 mg | PF-06651600 20 mg -> PF-06651600 50 mg | Placebo -> PF-06651600 50 mg | PF-06700841 60 mg -> PF-06700841 30 mg | PF-06700841 30 mg -> PF-06700841 30 mg | PF-06700841 10 mg -> PF-06700841 30 mg | Placebo -> PF-06700841 30 mg | Pooling Placebo During Chronic |
|---|---|---|---|---|---|---|---|---|---|
| COVID-19 pneumonia | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 |
| Viral infection | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 |
The number of participants with a laboratory abnormality meeting specified criteria while on study treatment or during lag time are reported here. Baseline is defined as the last measurement prior to receiving study treatment. The list of serum chemistry test parameters were as follows: blood urea nitrogen, creatinine, cystatin C, glucose, calcium, sodium, potassium, gamma glutamyl transferase, chloride, aspartate aminotransferase (AST), alanine aminotransferase (ALT), total bilirubin, direct bilirubin, alkaline phosphatase, uric acid, albumin, total protein, creatine kinase (CK), total cholesterol, triglycerides, high-density lipoproteins (HDL), and low-density lipoprotein (LDL).
| Participants | PF-06651600 200 mg -> PF-06651600 50 mg | PF-06651600 70 mg -> PF-06651600 50 mg | PF-06651600 20 mg -> PF-06651600 50 mg | Placebo -> PF-06651600 50 mg | PF-06700841 60 mg -> PF-06700841 30 mg | PF-06700841 30 mg -> PF-06700841 30 mg | PF-06700841 10 mg -> PF-06700841 30 mg | Placebo -> PF-06700841 30 mg | Pooling Placebo During Chronic |
|---|---|---|---|---|---|---|---|---|---|
| Bilirubin (mg/dL) >1.5 x ULN | 1 | 0 | 1 | 0 | 1 | 0 | 1 | 0 | 1 |
| Direct Bilirubin (mg/dL) >1.5 x ULN | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Indirect Bilirubin (mg/dL) >1.5 x ULN | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| AST (U/L) >3.0 x ULN | 0 | 0 | 2 | 0 | 0 | 0 | 0 | 0 | 0 |
| ALT (U/L) >3.0 x ULN | 1 | 0 | 1 | 0 | 0 | 0 | 2 | 0 | 0 |
| Gamma Glutamyl Transferase (U/L) >3.0 x ULN | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Alkaline Phosphatase (U/L) >3.0 x ULN | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 |
| Protein (g/dL) <0.8 x LLN | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Protein (g/dL) >1.2 x ULN | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Albumin (g/dL) <0.8 x LLN | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Albumin (g/dL) >1.2 x ULN | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Urea Nitrogen (mg/dL) >1.3 x ULN | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Creatinine (mg/dL) >1.3 x ULN | 0 | 1 | 0 | 0 | 0 | 1 | 1 | 0 | 0 |
| Urate (mg/dL) >1.2 x ULN | 0 | 2 | 0 | 0 | 0 | 1 | 1 | 0 | 0 |
| HDL Cholesterol (mg/dL) <0.8 x LLN | 1 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 |
| LDL Cholesterol (mg/dL) >1.2 x ULN | 1 | 1 | 0 | 0 | 1 | 0 | 2 | 1 | 0 |
| Triglycerides (mg/dL) >1.3 x ULN | 3 | 2 | 1 | 0 | 2 | 2 | 1 | 0 | 1 |
| Sodium (Meq/L) <0.95 x LLN | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Sodium (Meq/L) >1.05 x ULN | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Potassium (Meq/L) <0.9 x LLN | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 |
| Potassium (Meq/L) >1.1 x ULN | 1 | 0 | 0 | 0 | 2 | 0 | 0 | 0 | 0 |
| Chloride (Meq/L) <0.9 x LLN | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Chloride (Meq/L) >1.1 x ULN | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Calcium (mg/dL) <0.9 x LLN | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 |
| Calcium (mg/dL) >1.1 x ULN | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Glucose (mg/dL) <0.6 x LLN | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Glucose (mg/dL) >1.5 x ULN | 1 | 3 | 3 | 0 | 1 | 2 | 0 | 0 | 0 |
| Hemoglobin A1C (%) >1.3 x ULN | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Creatine Kinase (U/L) >2.0 x ULN | 1 | 3 | 2 | 1 | 3 | 10 | 2 | 0 | 1 |
| Cholesterol (mg/dl) >1.3 x ULN | 0 | 1 | 0 | 0 | 0 | 0 | 1 | 0 | 0 |
The number of participants with a laboratory abnormality meeting specified criteria while on study treatment or during lag time are reported here. Baseline is defined as the last measurement prior to receiving study treatment. The list of urinalysis test parameters were as follows:pH, glucose (qual), protein (qual), blood (qual), ketones, nitrites, leukocyte esterase, microscopy, and spot urine albumin/creatinine ratio. The criteria of laboratory abnormality is defined as one of the following conditions was met: 1)associated with accompanying symptoms;2)Test result requires additional diagnostic testing or medical/surgical intervention;3)Test result leads to a change in study dosing (outside of any protocol specified dose adjustments) or discontinuation from the study, significant additional concomitant drug treatment, or other therapy;4)Test result is considered to be an AE by the investigator or sponsor.
| Participants | PF-06651600 200 mg -> PF-06651600 50 mg | PF-06651600 70 mg -> PF-06651600 50 mg | PF-06651600 20 mg -> PF-06651600 50 mg | Placebo -> PF-06651600 50 mg | PF-06700841 60 mg -> PF-06700841 30 mg | PF-06700841 30 mg -> PF-06700841 30 mg | PF-06700841 10 mg -> PF-06700841 30 mg | Placebo -> PF-06700841 30 mg | Pooling Placebo During Chronic |
|---|---|---|---|---|---|---|---|---|---|
| pH (scalar) <4.5 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| pH (scalar) >8 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Urine Glucose (No Unit) >=1 | 1 | 2 | 1 | 1 | 1 | 1 | 0 | 0 | 1 |
| Ketones (No Unit) >=1 | 4 | 3 | 8 | 2 | 4 | 1 | 3 | 0 | 2 |
| Urine Protein (No Unit) >=1 | 0 | 1 | 3 | 0 | 1 | 0 | 2 | 0 | 1 |
| Urine Hemoglobin (No Unit) >=1 | 7 | 4 | 5 | 1 | 7 | 9 | 9 | 0 | 9 |
| Nitrite (No Unit) >=1 | 2 | 2 | 0 | 2 | 1 | 1 | 1 | 0 | 1 |
| Leukocyte Esterase (No Unit) >=1 | 8 | 13 | 11 | 1 | 14 | 7 | 8 | 1 | 9 |
| Urine Erythrocytes (/HPF) >=20 | 1 | 1 | 4 | 1 | 2 | 3 | 5 | 0 | 1 |
| Urine Leukocytes (/HPF) >=20 | 0 | 2 | 3 | 1 | 3 | 1 | 1 | 0 | 4 |
| Hyaline Casts (/LPF) >1 | 5 | 0 | 6 | 2 | 4 | 1 | 2 | 1 | 2 |
| WBC Casts (/LPF) >1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 |
| Bacteria (No Unit) >20 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 |
An AE was an untoward medical occurrence in a participant who received study treatment without regard to possibility of causal relationship. An SAE was an AE resulting in any of the following outcomes: death, life-threatening experience, initial or prolonged inpatient hospitalization, persistent or significant disability/incapacity, congenital anomaly/birth defect. Treatment-emergent AEs were those with initial onset or that worsen in severity after the first dose of study medication. All AEs mentioned below are treatment-emergent AEs.
| Participants | Placebo (Induction) | PF-06651600 20 mg (Induction) | PF-06651600 70 mg (Induction) | PF-06651600 200 mg (Induction) | PF-06700841 10 mg (Induction) | PF-06700841 30 mg (Induction) | PF-06700841 60 mg (Induction) |
|---|---|---|---|---|---|---|---|
| Participants with AEs | 13 | 23 | 21 | 21 | 19 | 26 | 23 |
| Participants with SAEs | 0 | 3 | 0 | 3 | 1 | 3 | 1 |
| Participants discontinued from study due to AEs | 0 | 5 | 0 | 5 | 1 | 2 | 1 |
The number of participants with a laboratory abnormality meeting the pre-specified criteria defined in the study protocol while on study treatment or during lag time are reported here. Baseline is defined as the last measurement prior to receiving study treatment. Laboratory data included hematology test, serum chemistry test, C-creative protein and viral surveillance. The criteria of laboratory abnormality is defined as one of the following conditions was met: 1)associated with accompanying symptoms;2)Test result requires additional diagnostic testing or medical/surgical intervention;3)Test result leads to a change in study dosing (outside of any protocol specified dose adjustments) or discontinuation from the study, significant additional concomitant drug treatment, or other therapy;4)Test result is considered to be an AE by the investigator or sponsor.
| Participants | Placebo (Induction) | PF-06651600 20 mg (Induction) | PF-06651600 70 mg (Induction) | PF-06651600 200 mg (Induction) | PF-06700841 10 mg (Induction) | PF-06700841 30 mg (Induction) | PF-06700841 60 mg (Induction) |
|---|---|---|---|---|---|---|---|
| Number of Participants With Laboratory Test Abnormalities (Induction Period) | 17 | 29 | 28 | 34 | 32 | 31 | 36 |
The number of participants with a laboratory abnormality meeting specified criteria while on study treatment or during lag time are reported here. Baseline is defined as the last measurement prior to receiving study treatment. The list of hematology test parameters were as follows: hemoglobin, hematocrit, red blood cell count, platelet count, white blood cell count, total neutrophils (absolute, Abs), eosinophils (Abs), monocytes (Abs), basophils (Abs), lymphocytes (Abs), prothrombin time (PT)/international normalized ratio (INR)/partial thromboplastin time (PTT), and reticulocytes (% and Abs). Percentages are displayed for the laboratory tests having a category with greater or equal to 1 evaluable participant.
| Participants | Placebo (Induction) | PF-06651600 20 mg (Induction) | PF-06651600 70 mg (Induction) | PF-06651600 200 mg (Induction) | PF-06700841 10 mg (Induction) | PF-06700841 30 mg (Induction) | PF-06700841 60 mg (Induction) |
|---|---|---|---|---|---|---|---|
| Hemoglobin (g/dL) <0.8× lower limit of normal (LLN) | 3 | 2 | 5 | 9 | 4 | 4 | 5 |
| Hematocrit (%) <0.8× LLN | 2 | 0 | 3 | 4 | 1 | 1 | 0 |
| Erythrocytes (10^6/mm^3) <0.8× LLN | 0 | 0 | 4 | 3 | 1 | 1 | 2 |
| Reticulocytes (Abs) (10^3/mm^3) <0.5× LLN | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Reticulocytes (Abs) (10^3/mm^3) >1.5× upper limit of normal (ULN) | 1 | 1 | 2 | 2 | 0 | 0 | 0 |
| Erythrocytes Mean Corpuscular Volume (10^-15L) <0.9× LLN | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Erythrocytes Mean Corpuscular Volume (10^-15L) >1.1× ULN | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Platelets (10^3/mm^3) <0.5× LLN | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Platelets (10^3/mm^3) >1.75× ULN | 1 | 0 | 0 | 0 | 2 | 2 | 5 |
| Reticulocytes/Erythrocytes (%) <0.5× LLN | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Reticulocytes/Erythrocytes (%) >1.5× ULN | 1 | 2 | 3 | 3 | 0 | 0 | 2 |
| Leukocytes (10^3/mm^3) <0.6× LLN | 0 | 0 | 0 | 0 | 1 | 0 | 0 |
| Leukocytes (10^3/mm^3) >1.5× ULN | 0 | 3 | 0 | 3 | 2 | 2 | 1 |
| Lymphocytes (Abs) (10^3/mm^3) <0.8× LLN | 3 | 2 | 4 | 11 | 2 | 1 | 2 |
| Lymphocytes (Abs) (10^3/mm^3) >1.2× ULN | 0 | 1 | 0 | 0 | 1 | 1 | 1 |
| Neutrophils (Abs) (10^3/mm^3) <0.8× LLN | 1 | 0 | 0 | 0 | 2 | 3 | 2 |
| Neutrophils (Abs) (10^3/mm^3) >1.2× ULN | 7 | 13 | 7 | 9 | 7 | 7 | 11 |
| Basophils (Abs) (10^3/mm^3) >1.2× ULN | 0 | 0 | 1 | 0 | 1 | 1 | 0 |
| Eosinophils (Abs) (10^3/mm^3) >1.2x ULN | 2 | 3 | 1 | 1 | 1 | 3 | 2 |
| Monocytes (Abs) (10^3/mm^3) >1.2× ULN | 2 | 2 | 0 | 2 | 1 | 1 | 2 |
| Activated PTT (second) >1.1× ULN | 1 | 0 | 1 | 0 | 0 | 0 | 0 |
| PT (second) >1.1× ULN | 1 | 2 | 1 | 1 | 0 | 0 | 0 |
| Prothrombin INR >1.1× ULN | 1 | 2 | 1 | 1 | 0 | 0 | 0 |
The number of participants with a laboratory abnormality meeting specified criteria while on study treatment or during lag time are reported here. Baseline is defined as the last measurement prior to receiving study treatment. The list of serum chemistry test parameters were as follows: blood urea nitrogen, creatinine, cystatin C, glucose, calcium, sodium, potassium, gamma glutamyl transferase, chloride, aspartate aminotransferase (AST), alanine aminotransferase (ALT), total bilirubin, direct bilirubin, alkaline phosphatase, uric acid, albumin, total protein, creatine kinase (CK), total cholesterol, triglycerides, high-density lipoproteins (HDL), and low-density lipoprotein (LDL)
| Participants | Placebo (Induction) | PF-06651600 20 mg (Induction) | PF-06651600 70 mg (Induction) | PF-06651600 200 mg (Induction) | PF-06700841 10 mg (Induction) | PF-06700841 30 mg (Induction) | PF-06700841 60 mg (Induction) |
|---|---|---|---|---|---|---|---|
| Bilirubin (mg/dL) >1.5x ULN | 0 | 1 | 0 | 1 | 2 | 2 | 1 |
| Direct Bilirubin (mg/dL) >1.5x ULN | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Indirect Bilirubin (mg/dL) >1.5x ULN | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| AST (U/L) >3.0x ULN | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| ALT (U/L) >3.0x ULN | 0 | 0 | 0 | 0 | 2 | 0 | 0 |
| Gamma Glutamyl Transferase (U/L) >3.0x ULN | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Alkaline Phosphatase (U/L) >3.0x ULN | 0 | 1 | 0 | 0 | 0 | 0 | 0 |
| Protein (g/dL) <0.8x LLN | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Protein (g/dL) >1.2x ULN | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Albumin (g/dL) <0.8x LLN | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Albumin (g/dL) >1.2x ULN | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Urea Nitrogen (mg/dL) >1.3x ULN | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Creatinine (mg/dL) >1.3x ULN | 0 | 0 | 0 | 0 | 0 | 1 | 0 |
| Urate (mg/dL) >1.2x ULN | 0 | 0 | 1 | 0 | 0 | 0 | 0 |
| HDL Cholesterol (mg/dL) <0.8x LLN | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| LDL Cholesterol (mg/dL) >1.2x ULN | 0 | 0 | 1 | 0 | 0 | 0 | 1 |
| Triglycerides (mg/dL) >1.3x ULN | 1 | 1 | 1 | 3 | 1 | 2 | 5 |
| Sodium(Meq/L) <0.95x LLN | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Sodium(Meq/L) >1.05x ULN | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Potassium (Meq/L) <0.9x LLN | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Potassium (Meq/L) >1.1x ULN | 0 | 0 | 1 | 0 | 0 | 0 | 0 |
| Chloride (Meq/L) <0.9x LLN | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Chloride (Meq/L) >1.1x ULN | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Calcium (mg/dL) <0.9x LLN | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Calcium (mg/dL) >1.1x ULN | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Glucose (mg/dL) <0.6x LLN | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Glucose (mg/dL) >1.5x ULN | 0 | 1 | 2 | 1 | 1 | 0 | 2 |
| Hemoglobin A1C (%) >1.3x ULN | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| CK (U/L) >2.0x ULN | 2 | 0 | 2 | 3 | 2 | 3 | 6 |
| Cholesterol (mg/dl) >1.3x ULN | 0 | 0 | 1 | 0 | 0 | 1 | 0 |
The number of participants with a laboratory abnormality meeting specified criteria while on study treatment or during lag time are reported here. Baseline is defined as the last measurement prior to receiving study treatment. The list of urinalysis test parameters were as follows:pH, glucose (qual), protein (qual), blood (qual), ketones, nitrites, leukocyte esterase, microscopy, and spot urine albumin/creatinine ratio. The criteria of laboratory abnormality is defined as one of the following conditions was met: 1)associated with accompanying symptoms;2)Test result requires additional diagnostic testing or medical/surgical intervention;3)Test result leads to a change in study dosing (outside of any protocol specified dose adjustments) or discontinuation from the study, significant additional concomitant drug treatment, or other therapy;4)Test result is considered to be an AE by the investigator or sponsor.
| Participants | Placebo (Induction) | PF-06651600 20 mg (Induction) | PF-06651600 70 mg (Induction) | PF-06651600 200 mg (Induction) | PF-06700841 10 mg (Induction) | PF-06700841 30 mg (Induction) | PF-06700841 60 mg (Induction) |
|---|---|---|---|---|---|---|---|
| pH (scalar) <4.5 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| pH (scalar) >8 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Urine glucose (no unit) ≥1 | 0 | 1 | 4 | 1 | 0 | 1 | 1 |
| Ketones (no unit) ≥1 | 1 | 4 | 1 | 1 | 7 | 4 | 4 |
| Urine protein(no unit) ≥1 | 0 | 2 | 0 | 1 | 1 | 2 | 0 |
| Urine hemoglobin(no unit) ≥1 | 2 | 4 | 4 | 4 | 5 | 8 | 4 |
| Nitrite (no unit) ≥1 | 1 | 1 | 2 | 1 | 2 | 0 | 1 |
| Leukocyte esterase (no unit) ≥1 | 3 | 11 | 4 | 10 | 7 | 8 | 14 |
| Urine erythrocytes (/HPF) ≥20 | 0 | 0 | 1 | 1 | 0 | 0 | 0 |
| Urine leukocytes (/HPF) ≥20 | 1 | 2 | 1 | 4 | 3 | 1 | 3 |
| Granular casts (/LPF) >1 | 1 | 0 | 0 | 1 | 0 | 0 | 0 |
| Hyaline casts (/LPF) >1 | 3 | 2 | 2 | 4 | 4 | 2 | 1 |
| WBC casts (/LPF) >1 | 0 | 0 | 1 | 0 | 0 | 0 | 0 |
| Bacteria (no unit) >20 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
The vital signs data included the single sitting blood pressure, pulse rate and temperature. The criteria of vital sign abnormality are indicated below.
| Participants | Placebo (Induction) | PF-06651600 20 mg (Induction) | PF-06651600 70 mg (Induction) | PF-06651600 200 mg (Induction) | PF-06700841 10 mg (Induction) | PF-06700841 30 mg (Induction) | PF-06700841 60 mg (Induction) |
|---|---|---|---|---|---|---|---|
| Sitting Systolic Blood Pressure Value <90 mmHg | 0 | 1 | 1 | 0 | 3 | 0 | 0 |
| Sitting Systolic Blood Pressure Change ≥30 mmHg Increase | 0 | 1 | 3 | 0 | 0 | 0 | 3 |
| Sitting Systolic Blood Pressure Change ≥30 mmHg Decrease | 0 | 1 | 0 | 0 | 0 | 1 | 0 |
| Sitting Diastolic Blood Pressure Value <50 mmHg | 0 | 0 | 1 | 0 | 0 | 0 | 0 |
| Sitting Diastolic Blood Pressure Change ≥20 mmHg Increase | 0 | 2 | 3 | 0 | 2 | 1 | 5 |
| Sitting Diastolic Blood Pressure Change ≥20 mmHg Decrease | 0 | 4 | 4 | 2 | 2 | 1 | 2 |
| Sitting Pulse Rate Value <40 bpm | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Sitting Pulse Rate Value >120 bpm | 0 | 1 | 0 | 0 | 0 | 0 | 0 |
The number of participants with abnormal ECG findings during the induction period (from Day 1 to Week 8) are reported below. The criteria of test abnormality is defined as one of the following conditions was met: 1)associated with accompanying symptoms;2)Test result requires additional diagnostic testing or medical/surgical intervention;3)Test result leads to a change in study dosing (outside of any protocol specified dose adjustments) or discontinuation from the study, significant additional concomitant drug treatment, or other therapy;4)Test result is considered to be an AE by the investigator or sponsor.
| Participants | Placebo (Induction) | PF-06651600 20 mg (Induction) | PF-06651600 70 mg (Induction) | PF-06651600 200 mg (Induction) | PF-06700841 10 mg (Induction) | PF-06700841 30 mg (Induction) | PF-06700841 60 mg (Induction) |
|---|---|---|---|---|---|---|---|
| abnormal, not clinical significant (at screening) | 2 | 8 | 6 | 4 | 9 | 10 | 8 |
| abnormal, clinical significant (at screening) | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| abnormal, not clinical significant (at Week 8) | 2 | 7 | 8 | 4 | 5 | 4 | 3 |
| abnormal, clinical significant (at Week 8) | 0 | 0 | 0 | 1 | 0 | 0 | 0 |
Serious infections was defined as any infection (for example, viral, bacterial, and fungal) requiring hospitalization or parenteral antimicrobials including Listeria encephalitis, Pneumonia, Viral infection.
| Participants | Placebo (Induction) | PF-06651600 20 mg (Induction) | PF-06651600 70 mg (Induction) | PF-06651600 200 mg (Induction) | PF-06700841 10 mg (Induction) | PF-06700841 30 mg (Induction) | PF-06700841 60 mg (Induction) |
|---|---|---|---|---|---|---|---|
| Listeria encephalitis | 0 | 0 | 0 | 1 | 0 | 0 | 0 |
| Pneumonia | 0 | 1 | 0 | 0 | 0 | 0 | 0 |
| Viral infection | 0 | 1 | 0 | 0 | 0 | 0 | 0 |
The Mayo Score is a tool designed to measure disease activity for ulcerative colitis. The Mayo scoring system ranges from 0 to 12 points and consists of 4 subscores, which are stool frequency, rectal bleeding, findings on endoscopy and physician's global assessment. Each subscore graded 0 to 3 with the higher score indicating more severe disease activity. Clinical remission was defined as total Mayo score of 2 points or lower, with no individual subscore exceeding 1 point and a rectal bleeding subscore of 0.
| Percentage of participants | Placebo (Induction) | PF-06651600 20 mg (Induction) | PF-06651600 70 mg (Induction) | PF-06651600 200 mg (Induction) | PF-06700841 10 mg (Induction) | PF-06700841 30 mg (Induction) | PF-06700841 60 mg (Induction) |
|---|---|---|---|---|---|---|---|
| Percentage of Participants Achieving Remission Based on Total Mayo Score at Week 8 (Induction Period) | 0 (0.0 to 11.0) | 9.8 (4.8 to 19.1) | 28.6 (19.0 to 40.4) | 34.0 (24.0 to 45.4) | 8.3 (3.7 to 16.8) | 23.4 (14.8 to 34.5) | 23.4 (14.8 to 34.5) |
The Mayo Score is a tool designed to measure disease activity for ulcerative colitis. The Mayo scoring system ranges from 0 to 12 points and consists of 4 subscores, which are stool frequency, rectal bleeding, findings on endoscopy and physician's global assessment. Each subscore graded 0 to 3 with the higher score indicating more severe disease activity. Improvement in endoscopic subscore appearance was defined at Mayo endoscopic subscore of ≤1.
| Percentage of participants | Placebo (Induction) | PF-06651600 20 mg (Induction) | PF-06651600 70 mg (Induction) | PF-06651600 200 mg (Induction) | PF-06700841 10 mg (Induction) | PF-06700841 30 mg (Induction) | PF-06700841 60 mg (Induction) |
|---|---|---|---|---|---|---|---|
| Percentage of Participants Achieving Improvement in Endoscopic Appearance Based on Total Mayo Score at Week 8 (Induction Period) | 0 (0.0 to 11.0) | 21.6 (13.5 to 33.1) | 34.7 (24.4 to 46.4) | 42.0 (30.3 to 54.6) | 20.8 (11.8 to 31.5) | 31.9 (20.8 to 44.4) | 29.8 (19.9 to 42.3) |
The Mayo Score is a tool designed to measure disease activity for ulcerative colitis. The Mayo scoring system ranges from 0 to 12 points and consists of 4 subscores, which are stool frequency, rectal bleeding, findings on endoscopy and physician's global assessment. Each subscore graded 0 to 3 with the higher score indicating more severe disease activity. Clinical response was defined as decrease from baseline in total Mayo score of at least 3 points and at least 30%, with an accompanying decrease in the subscore for rectal bleeding of at least 1 point or absolute subscore for rectal bleeding of 0 or 1.
| Percentage of participants | Placebo (Induction) | PF-06651600 20 mg (Induction) | PF-06651600 70 mg (Induction) | PF-06651600 200 mg (Induction) | PF-06700841 10 mg (Induction) | PF-06700841 30 mg (Induction) | PF-06700841 60 mg (Induction) |
|---|---|---|---|---|---|---|---|
| Percentage of Participants Achieving Clinical Response Based on Total Mayo Score at Week 8 (Induction Period) | 24.0 (11.0 to 41.7) | 41.2 (29.9 to 53.6) | 69.4 (57.6 to 80.1) | 68.0 (56.6 to 78.8) | 41.7 (29.6 to 54.5) | 53.2 (40.3 to 65.5) | 61.7 (48.7 to 72.9) |
The Mayo Score is a tool designed to measure disease activity for ulcerative colitis. The Mayo scoring system ranges from 0 to 12 points and consists of 4 subscores, which are stool frequency, rectal bleeding, findings on endoscopy and physician's global assessment. Each subscore graded 0 to 3 with the higher score indicating more severe disease activity. Endoscopic remission was defined as endoscopic subscore of 0.
| Percentage of participants | Placebo (Induction) | PF-06651600 20 mg (Induction) | PF-06651600 70 mg (Induction) | PF-06651600 200 mg (Induction) | PF-06700841 10 mg (Induction) | PF-06700841 30 mg (Induction) | PF-06700841 60 mg (Induction) |
|---|---|---|---|---|---|---|---|
| Percentage of Participants Achieving Endoscopic Remission Based on Total Mayo Score at Week 8 (Induction Period) | 0 (0.0 to 11.0) | 3.9 (1.0 to 11.0) | 8.2 (3.6 to 16.5) | 12.0 (5.4 to 21.2) | 2.1 (0.2 to 8.6) | 17.0 (8.8 to 28.3) | 8.5 (3.8 to 17.2) |
The Mayo Score is a tool designed to measure disease activity for ulcerative colitis. The Mayo scoring system ranges from 0 to 12 points and consists of 4 subscores, which are stool frequency, rectal bleeding, findings on endoscopy and physician's global assessment. Each subscore graded 0 to 3 with the higher score indicating more severe disease activity. Symptomatic remission was defined as total Mayo score of 2 points or lower, with no individual subscore exceeding 1 point, and both rectal bleeding and stool frequency subscores of 0.
| Percentage of participants | Placebo (Induction) | PF-06651600 20 mg (Induction) | PF-06651600 70 mg (Induction) | PF-06651600 200 mg (Induction) | PF-06700841 10 mg (Induction) | PF-06700841 30 mg (Induction) | PF-06700841 60 mg (Induction) |
|---|---|---|---|---|---|---|---|
| Percentage of Participants Achieving Symptomatic Remission Based on Total Mayo Score at Week 8 (Induction Period) | 0 (0.0 to 11.0) | 7.8 (3.5 to 15.9) | 16.3 (8.4 to 27.1) | 26.0 (16.2 to 37.6) | 6.3 (2.3 to 15.1) | 14.9 (8.0 to 25.1) | 14.9 (8.0 to 25.1) |
The Mayo Score is a tool designed to measure disease activity for ulcerative colitis. The Mayo scoring system ranges from 0 to 12 points and consists of 4 subscores, which are stool frequency, rectal bleeding, findings on endoscopy and physician's global assessment. Each subscore graded 0 to 3 with the higher score indicating more severe disease activity. Deep remission was defined as total Mayo score of 2 points or lower, with no individual subscore exceeding 1 point and a zero on both endoscopic and rectal bleeding subscore.
| Percentage of participants | Placebo (Induction) | PF-06651600 20 mg (Induction) | PF-06651600 70 mg (Induction) | PF-06651600 200 mg (Induction) | PF-06700841 10 mg (Induction) | PF-06700841 30 mg (Induction) | PF-06700841 60 mg (Induction) |
|---|---|---|---|---|---|---|---|
| Percentage of Participants Achieving Deep Remission Based on Total Mayo Score at Week 8 (Induction Period) | 0 (0.0 to 11.0) | 3.9 (1.0 to 11.0) | 8.2 (3.6 to 16.5) | 12.0 (5.4 to 21.2) | 0 (0.0 to 5.6) | 14.9 (8.0 to 25.1) | 6.4 (2.4 to 15.4) |
The Mayo Score is a tool designed to measure disease activity for ulcerative colitis. The Mayo scoring system ranges from 0 to 12 points and consists of 4 subscores, which are stool frequency, rectal bleeding, findings on endoscopy and physician's global assessment. Each subscore graded 0 to 3 with the higher score indicating more severe disease activity. The partial Mayo score does not incorporate the endoscopy score and the partial Mayo score ranges from 0 to 9.
| Units on a scale | Placebo (Induction) | PF-06651600 20 mg (Induction) | PF-06651600 70 mg (Induction) | PF-06651600 200 mg (Induction) | PF-06700841 10 mg (Induction) | PF-06700841 30 mg (Induction) | PF-06700841 60 mg (Induction) |
|---|---|---|---|---|---|---|---|
| Week 2 | -0.66 ± 0.37 | -1.65 ± 0.26 | -2.56 ± 0.26 | -3.19 ± 0.27 | -1.6 ± 0.27 | -1.64 ± 0.27 | -2.45 ± 0.27 |
| Week 4 | -1.64 ± 0.42 | -2.24 ± 0.29 | -3.29 ± 0.30 | -4.24 ± 0.31 | -2.31 ± 0.30 | -2.06 ± 0.30 | -2.95 ± 0.30 |
| Week 8 | -1.15 ± 0.43 | -2.54 ± 0.30 | -4.06 ± 0.30 | -4.69 ± 0.32 | -2.51 ± 0.30 | -2.71 ± 0.31 | -3.47 ± 0.31 |
The Mayo Score is a tool designed to measure disease activity for ulcerative colitis. The Mayo scoring system ranges from 0 to 12 points and consists of 4 subscores, which are stool frequency, rectal bleeding, findings on endoscopy and physician's global assessment. Each subscore graded 0 to 3 with the higher score indicating more severe disease activity.
| Units on a scale | Placebo (Induction) | PF-06651600 20 mg (Induction) | PF-06651600 70 mg (Induction) | PF-06651600 200 mg (Induction) | PF-06700841 10 mg (Induction) | PF-06700841 30 mg (Induction) | PF-06700841 60 mg (Induction) |
|---|---|---|---|---|---|---|---|
| Change From Baseline in Total Mayo Score at Week 8 (Induction Period) | -1.14 (-2.06 to -0.22) | -3.17 (-3.83 to -2.51) | -5.02 (-5.68 to -4.36) | -5.74 (-6.43 to -5.06) | -2.93 (-3.58 to -2.29) | -3.42 (-4.08 to -2.76) | -4.35 (-5.00 to -3.69) |
IBDQ is a psychometrically validated patient reported outcome (PRO) instrument for measuring the disease specific quality of life in participants with inflammatory bowel disease (IBD). The IBDQ is comprised of 32 items, which are grouped into 4 dimensions: bowel function, emotional status, systemic symptoms and social function. The 4 domains are scored as follows: Bowel symptoms: 10 to 70; Systemic symptoms: 5 to 35.; Emotional function: 12 to 84; Social function: 5 to 35. The total IBDQ score ranges from 32 to 224. For the total score and each domain, a higher score indicates better quality of life.
| Units on a scale | Placebo (Induction) | PF-06651600 20 mg (Induction) | PF-06651600 70 mg (Induction) | PF-06651600 200 mg (Induction) | PF-06700841 10 mg (Induction) | PF-06700841 30 mg (Induction) | PF-06700841 60 mg (Induction) |
|---|---|---|---|---|---|---|---|
| Baseline (Bowel Systems Domain score) | 35.80 (32.48 to 39.12) | 34.29 (31.74 to 36.85) | 33.71 (31.41 to 36.01) | 34.84 (32.66 to 37.01) | 34.17 (32.13 to 36.21) | 32.38 (29.99 to 34.77) | 33.38 (31.36 to 35.40) |
| Week 4 (Bowel Systems Domain score) | 44.87 (40.65 to 49.09) | 46.98 (44.05 to 49.91) | 51.00 (48.45 to 53.55) | 53.80 (50.83 to 56.76) | 44.93 (42.00 to 47.86) | 46.84 (43.56 to 50.12) | 50.64 (47.66 to 53.61) |
| Week 8 (Bowel Systems Domain score) | 44.68 (41.37 to 47.99) | 47.96 (44.68 to 51.23) | 54.27 (51.38 to 57.16) | 55.95 (53.40 to 58.50) | 46.87 (43.46 to 50.27) | 50.12 (47.12 to 53.11) | 53.45 (50.53 to 56.38) |
| Baseline (Emotion Health Domain score) | 43.76 (38.81 to 48.71) | 42.76 (39.37 to 46.16) | 42.90 (39.56 to 46.24) | 41.39 (37.88 to 44.90) | 42.40 (39.15 to 45.65) | 38.74 (35.59 to 41.90) | 41.43 (38.56 to 44.29) |
| Week 4(Emotion Health Domain score) | 54.74 (49.67 to 59.81) | 53.65 (49.92 to 57.39) | 59.89 (56.83 to 62.96) | 61.11 (57.54 to 64.68) | 52.43 (48.26 to 56.61) | 52.77 (48.99 to 56.55) | 57.86 (54.06 to 61.67) |
| Week 8(Emotion Health Domain score) | 52.50 (47.61 to 57.39) | 54.23 (50.29 to 58.17) | 62.73 (59.30 to 66.17) | 63.12 (59.28 to 66.96) | 54.44 (50.02 to 58.87) | 56.86 (53.34 to 60.38) | 60.89 (57.09 to 64.69) |
| Baseline (Systemic Systems Domain score) | 16.56 (14.83 to 18.29) | 16.12 (14.74 to 17.50) | 15.98 (14.67 to 17.29) | 15.41 (14.14 to 16.68) | 16.30 (14.93 to 17.67) | 15.21 (14.06 to 16.36) | 16.72 (15.40 to 18.05) |
| Week 4(Systemic Systems Domain score) | 20.87 (18.56 to 23.18) | 21.70 (20.34 to 23.05) | 23.74 (22.44 to 25.05) | 23.66 (22.08 to 25.23) | 20.70 (19.03 to 22.36) | 20.77 (19.24 to 22.30) | 23.61 (21.89 to 25.34) |
| Week 8(Systemic Systems Domain score) | 20.82 (19.11 to 22.53) | 21.85 (20.20 to 23.50) | 24.40 (22.91 to 25.89) | 25.51 (24.17 to 26.86) | 21.40 (19.56 to 23.24) | 23.07 (21.50 to 24.64) | 24.48 (22.72 to 26.24) |
| Baseline (Social Function Domain score) | 16.88 (14.41 to 19.35) | 17.25 (15.43 to 19.08) | 16.59 (14.70 to 18.48) | 17.31 (15.73 to 18.88) | 17.30 (15.69 to 18.91) | 14.91 (13.28 to 16.55) | 16.64 (15.06 to 18.22) |
| Week 4 (Social Function Domain score) | 22.57 (19.80 to 25.33) | 22.41 (20.57 to 24.25) | 26.21 (24.73 to 27.70) | 28.20 (26.42 to 29.99) | 22.83 (20.78 to 24.87) | 23.02 (20.82 to 25.23) | 24.86 (22.55 to 27.17) |
| Week 8 (Social Function Domain score) | 21.91 (19.27 to 24.55) | 23.45 (21.45 to 25.44) | 27.02 (25.06 to 28.99) | 29.80 (28.14 to 31.47) | 24.36 (22.11 to 26.60) | 25.12 (22.88 to 27.35) | 26.57 (24.50 to 28.63) |
| Baseline (Total IBDQ score) | 113.00 (101.49 to 124.51) | 110.43 (101.85 to 119.01) | 109.18 (101.30 to 117.07) | 108.94 (101.20 to 116.68) | 110.17 (102.94 to 117.40) | 101.26 (93.85 to 108.66) | 108.17 (101.13 to 115.21) |
| Week 4 (Total IBDQ score) | 143.04 (129.90 to 156.19) | 144.74 (135.60 to 153.88) | 160.85 (153.50 to 168.20) | 166.77 (157.55 to 176.00) | 140.89 (130.88 to 150.90) | 143.41 (133.62 to 153.20) | 156.98 (146.69 to 167.27) |
| Week 8 (Total IBDQ score) | 139.91 (128.72 to 151.10) | 147.49 (137.17 to 157.80) | 168.42 (159.53 to 177.31) | 174.39 (165.67 to 183.11) | 147.07 (135.79 to 158.35) | 155.16 (145.67 to 164.65) | 165.39 (155.29 to 175.49) |
IBDQ is a psychometrically validated PRO instrument for measuring the disease specific quality of life in participants with IBD. The IBDQ is comprised of 32 items, which are grouped into 4 dimensions: bowel function, emotional status, systemic symptoms and social function. The 4 domains are scored as follows: Bowel symptoms: 10 to 70; Systemic symptoms: 5 to 35.; Emotional function: 12 to 84; Social function: 5 to 35. The total IBDQ score ranges from 32 to 224. For the total score and each domain, a higher score indicates better quality of life. Baseline value is defined as the last non-missing measurement collected prior to or on Day 1.
| Units on a scale | Placebo (Induction) | PF-06651600 20 mg (Induction) | PF-06651600 70 mg (Induction) | PF-06651600 200 mg (Induction) | PF-06700841 10 mg (Induction) | PF-06700841 30 mg (Induction) | PF-06700841 60 mg (Induction) |
|---|---|---|---|---|---|---|---|
| Week 4 | 30.30 ± 6.51 | 33.71 ± 4.60 | 51.12 ± 4.61 | 57.01 ± 4.78 | 28.45 ± 4.68 | 37.94 ± 4.72 | 49.79 ± 4.73 |
| Week 8 | 24.23 ± 7.40 | 37.91 ± 5.15 | 59.20 ± 5.23 | 62.17 ± 5.47 | 36.60 ± 5.29 | 48.81 ± 5.33 | 56.39 ± 5.33 |
IBDQ is a psychometrically validated PRO instrument for measuring the disease specific quality of life in participants with IBD. The IBDQ is comprised of 32 items, which are grouped into 4 dimensions: bowel function, emotional status, systemic symptoms and social function. The 4 domains are scored as follows: Bowel symptoms: 10 to 70; Systemic symptoms: 5 to 35.; Emotional function: 12 to 84; Social function: 5 to 35. The total IBDQ score ranges from 32 to 224. For the total score and each domain, a higher score indicates better quality of life.
| Percentage of participants | Placebo (Induction) | PF-06651600 20 mg (Induction) | PF-06651600 70 mg (Induction) | PF-06651600 200 mg (Induction) | PF-06700841 10 mg (Induction) | PF-06700841 30 mg (Induction) | PF-06700841 60 mg (Induction) |
|---|---|---|---|---|---|---|---|
| Week 4 | 24.0 (11.0 to 41.7) | 21.6 (13.5 to 33.1) | 40.8 (28.9 to 53.6) | 46.0 (34.2 to 58.5) | 27.1 (16.8 to 39.4) | 27.7 (17.2 to 40.3) | 38.3 (27.1 to 51.3) |
| Week 8 | 20.0 (10.1 to 36.2) | 29.4 (19.1 to 40.6) | 57.1 (44.4 to 69.2) | 44.0 (33.0 to 56.6) | 31.3 (20.4 to 43.4) | 40.4 (28.3 to 53.5) | 51.1 (38.9 to 62.8) |
IBDQ is a psychometrically validated PRO instrument for measuring the disease specific quality of life in participants with IBD. The IBDQ is comprised of 32 items, which are grouped into 4 dimensions: bowel function, emotional status, systemic symptoms and social function. The 4 domains are scored as follows: Bowel symptoms: 10 to 70; Systemic symptoms: 5 to 35.; Emotional function: 12 to 84; Social function: 5 to 35. The total IBDQ score ranges from 32 to 224. For the total score and each domain, a higher score indicates better quality of life.
| Percentage of participants | Placebo (Induction) | PF-06651600 20 mg (Induction) | PF-06651600 70 mg (Induction) | PF-06651600 200 mg (Induction) | PF-06700841 10 mg (Induction) | PF-06700841 30 mg (Induction) | PF-06700841 60 mg (Induction) |
|---|---|---|---|---|---|---|---|
| Week 4 | 48.0 (30.7 to 64.0) | 60.8 (48.4 to 72.3) | 83.7 (72.9 to 91.6) | 80.0 (69.7 to 88.7) | 64.6 (52.5 to 75.3) | 78.7 (67.8 to 88.0) | 72.3 (59.7 to 82.8) |
| Week 8 | 56.0 (38.9 to 73.0) | 54.9 (42.5 to 66.9) | 79.6 (69.2 to 88.5) | 70.0 (58.5 to 80.5) | 62.5 (50.0 to 73.6) | 80.9 (69.7 to 88.8) | 78.7 (67.8 to 88.0) |
IBDQ is a psychometrically validated PRO instrument for measuring the disease specific quality of life in participants with IBD. The IBDQ is comprised of 32 items, which are grouped into 4 dimensions: bowel function, emotional status, systemic symptoms and social function. The 4 domains are scored as follows: Bowel symptoms: 10 to 70; Systemic symptoms: 5 to 35.; Emotional function: 12 to 84; Social function: 5 to 35. The total IBDQ score ranges from 32 to 224. For the total score and each domain, a higher score indicates better quality of life. The improvement in IBDQ bowel symptom domain was defined as an increase of ≥1.2 points from baseline in average score among bowel symptoms domain (items 1, 5, 9, 13, 17, 20, 22, 24, 26, 29).
| Percentage of participants | Placebo (Induction) | PF-06651600 20 mg (Induction) | PF-06651600 70 mg (Induction) | PF-06651600 200 mg (Induction) | PF-06700841 10 mg (Induction) | PF-06700841 30 mg (Induction) | PF-06700841 60 mg (Induction) |
|---|---|---|---|---|---|---|---|
| Week 4 | 20.0 (10.1 to 36.2) | 51.0 (38.7 to 63.2) | 65.3 (53.6 to 75.6) | 64.0 (42.6 to 75.1) | 37.5 (26.4 to 50.0) | 53.2 (40.3 to 65.5) | 57.5 (44.4 to 69.7) |
| Week 8 | 24.0 (11.0 to 41.7) | 47.1 (35.0 to 59.4) | 69.4 (57.6 to 80.1) | 62.0 (50.0 to 73.5) | 50.0 (37.6 to 62.4) | 63.8 (51.3 to 74.9) | 66.0 (53.5 to 77.3) |
The SF-36 version 2 (Acute version) is a 36-item generic health status measure. It measures 8 general health concepts or domains: Physical Functioning (PF), Role-Physical (RP), Bodily Pain (BP), General Health (GH), Vitality (VT), Social Functioning (SF), Role-Emotional (RE), and Mental Health (MH). These 8 domains can also be summarized as physical and mental component scores. The summary component scores, Physical Component Summary (PCS) and Mental Component Summary (MCS), are based on a normalized sum of the 8 scale scores PF, RP, BP, GH, VT, SF, RE, and MH . All domains and summary components are scored such that a higher score indicates a higher functioning or health level. The minimum and maximum scores of the PCS Score are 6.1 and 79.7, respectively. The minimum and maximum scores of the MCS Score are -3.8 and 78.7, respectively.
| Units on a scale | Placebo (Induction) | PF-06651600 20 mg (Induction) | PF-06651600 70 mg (Induction) | PF-06651600 200 mg (Induction) | PF-06700841 10 mg (Induction) | PF-06700841 30 mg (Induction) | PF-06700841 60 mg (Induction) |
|---|---|---|---|---|---|---|---|
| Week 4 (PCS) | 4.69 (2.59 to 6.80) | 5.90 (4.41 to 7.39) | 6.36 (4.88 to 7.85) | 9.21 (7.67 to 10.76) | 5.67 (4.16 to 7.19) | 5.85 (4.31 to 7.38) | 6.40 (4.87 to 7.93) |
| Week 8 (PCS) | 5.37 (2.96 to 7.77) | 5.85 (4.19 to 7.52) | 8.66 (6.97 to 10.35) | 10.86 (9.08 to 12.64) | 6.29 (4.57 to 8.02) | 8.21 (6.47 to 9.95) | 8.55 (6.83 to 10.27) |
| Week 4(MCS) | 7.83 (4.59 to 11.06) | 4.95 (2.67 to 7.23) | 7.79 (5.50 to 10.07) | 8.81 (6.43 to 11.18) | 2.44 (0.13 to 4.74) | 7.46 (5.11 to 9.82) | 9.28 (6.93 to 11.62) |
| Week 8(MCS) | 4.24 (0.69 to 7.78) | 5.18 (2.72 to 7.64) | 9.72 (7.22 to 12.22) | 9.41 (6.79 to 12.03) | 5.22 (2.70 to 7.75) | 8.04 (5.48 to 10.61) | 10.01 (7.47 to 12.55) |
For EQ-5D 3L, participant rated questionnaire to assess generic health status in two parts: single utility score and visual analog scale. For utility score, participants rated their current health state on 5 dimensions: mobility, self-care, usual activities, pain and discomfort, and anxiety and depression with each dimension having three levels of function: 1 indicates no problem; 2 indicates some problem; 3 indicates extreme problem. Scoring formula developed by EuroQol Group assigns a utility value for each domain in the profile. Score was transformed and results in a total score range of 0.05 to 1.00; higher scores indicating a better health state. The EQ-5D VAS records the respondent's self rated health on a scale from 0 (worst imaginable health state) to 100 (best imaginable health state).
| Units on a scale | Placebo (Induction) | PF-06651600 20 mg (Induction) | PF-06651600 70 mg (Induction) | PF-06651600 200 mg (Induction) | PF-06700841 10 mg (Induction) | PF-06700841 30 mg (Induction) | PF-06700841 60 mg (Induction) |
|---|---|---|---|---|---|---|---|
| EQ-5D 3L Utility Score (Week 4) | 0.11 (0.06 to 0.16) | 0.07 (0.04 to 0.11) | 0.12 (0.09 to 0.15) | 0.13 (0.10 to 0.17) | 0.07 (0.03 to 0.10) | 0.11 (0.08 to 0.14) | 0.12 (0.09 to 0.15) |
| EQ-5D 3L Utility Score (Week 8) | 0.08 (0.03 to 0.13) | 0.08 (0.05 to 0.12) | 0.15 (0.11 to 0.18) | 0.15 (0.12 to 0.19) | 0.09 (0.05 to 0.13) | 0.13 (0.10 to 0.17) | 0.14 (0.11 to 0.18) |
| EQ-5D VAS Score (Week 4) | 8.41 (2.18 to 14.63) | 13.60 (9.20 to 18.00) | 16.35 (11.96 to 20.74) | 17.45 (12.88 to 22.02) | 10.48 (6.04 to 14.92) | 12.24 (7.72 to 16.77) | 14.44 (9.90 to 18.97) |
| EQ-5D VAS Score (Week 8) | 13.17 (6.48 to 19.85) | 13.11 (8.48 to 17.74) | 18.88 (14.17 to 23.60) | 22.54 (17.60 to 27.49) | 10.35 (5.58 to 15.12) | 17.11 (12.28 to 21.94) | 20.01 (15.21 to 24.81) |
The Mayo Score is a tool designed to measure disease activity for ulcerative colitis. The Mayo scoring system ranges from 0 to 12 points and consists of 4 subscores, which are stool frequency, rectal bleeding, findings on endoscopy and physician's global assessment. Each subscore graded 0 to 3 with the higher score indicating more severe disease activity.
| Units on a scale | Placebo -> PF-06651600 50 mg | PF-06651600 20 mg -> PF-06651600 50 mg | PF-06651600 70 mg -> PF-06651600 50 mg | PF-06651600 200 mg -> PF-06651600 50 mg | Placebo -> PF-06700841 30 mg | PF-06700841 10 mg -> PF-06700841 30 mg | PF-06700841 60 mg -> PF-06700841 30 mg | PF-06700841 30 mg -> PF-06700841 30 mg |
|---|---|---|---|---|---|---|---|---|
| Total Mayo Score at Week 32 (Chronic Period) | 4.13 (2.82 to 5.44) | 3.47 (2.75 to 4.19) | 3.46 (2.77 to 4.16) | 2.89 (2.18 to 3.60) | 4.62 (2.62 to 6.61) | 3.81 (2.94 to 4.68) | 3.63 (2.67 to 4.59) | 3.86 (2.98 to 4.75) |
The Mayo Score is a tool designed to measure disease activity for ulcerative colitis. The Mayo scoring system ranges from 0 to 12 points and consists of 4 subscores, which are stool frequency, rectal bleeding, findings on endoscopy and physician's global assessment. Each subscore graded 0 to 3 with the higher score indicating more severe disease activity. Clinical remission was defined as total Mayo score of 2 points or lower, with no individual subscore exceeding 1 point and a rectal bleeding subscore of 0.
| Percentage of participants | Placebo -> PF-06651600 50 mg | PF-06651600 20 mg -> PF-06651600 50 mg | PF-06651600 70 mg -> PF-06651600 50 mg | PF-06651600 200 mg -> PF-06651600 50 mg | Placebo -> PF-06700841 30 mg | PF-06700841 10 mg -> PF-06700841 30 mg | PF-06700841 60 mg -> PF-06700841 30 mg | PF-06700841 30 mg -> PF-06700841 30 mg |
|---|---|---|---|---|---|---|---|---|
| Percentage of Participants Achieving Remission Based on Total Mayo Score at Week 32 (Chronic Period) | 16.7 (4.5 to 39.8) | 23.9 (15.1 to 35.0) | 28.6 (17.4 to 41.0) | 34.1 (22.3 to 46.5) | 18.2 (4.9 to 43.6) | 21.4 (12.6 to 34.2) | 26.8 (17.1 to 39.8) | 26.8 (17.1 to 39.8) |
The Mayo Score is a tool designed to measure disease activity for ulcerative colitis. The Mayo scoring system ranges from 0 to 12 points and consists of 4 subscores, which are stool frequency, rectal bleeding, findings on endoscopy and physician's global assessment. Each subscore graded 0 to 3 with the higher score indicating more severe disease activity. Improvement in endoscopic appearance was defined at Mayo endoscopic subscore of ≤1.
| Percentage of participants | Placebo -> PF-06651600 50 mg | PF-06651600 20 mg -> PF-06651600 50 mg | PF-06651600 70 mg -> PF-06651600 50 mg | PF-06651600 200 mg -> PF-06651600 50 mg | Placebo -> PF-06700841 30 mg | PF-06700841 10 mg -> PF-06700841 30 mg | PF-06700841 60 mg -> PF-06700841 30 mg | PF-06700841 30 mg -> PF-06700841 30 mg |
|---|---|---|---|---|---|---|---|---|
| Percentage of Participants Achieving Improvement in Endoscopic Appearance Based on Mayo Score at Week 32 (Chronic Period) | 33.3 (15.4 to 60.2) | 26.1 (15.8 to 37.7) | 40.5 (27.7 to 54.3) | 34.1 (22.3 to 46.5) | 18.2 (4.9 to 43.6) | 31.0 (19.4 to 43.3) | 34.1 (23.0 to 46.9) | 36.6 (24.6 to 50.0) |
The Mayo Score is a tool designed to measure disease activity for ulcerative colitis. The Mayo scoring system ranges from 0 to 12 points and consists of 4 subscores, which are stool frequency, rectal bleeding, findings on endoscopy and physician's global assessment. Each subscore graded 0 to 3 with the higher score indicating more severe disease activity.
| Units on a scale | Placebo -> PF-06651600 50 mg | PF-06651600 20 mg -> PF-06651600 50 mg | PF-06651600 70 mg -> PF-06651600 50 mg | PF-06651600 200 mg -> PF-06651600 50 mg | Placebo -> PF-06700841 30 mg | PF-06700841 10 mg -> PF-06700841 30 mg | PF-06700841 60 mg -> PF-06700841 30 mg | PF-06700841 30 mg -> PF-06700841 30 mg |
|---|---|---|---|---|---|---|---|---|
| Change From Baseline in Total Mayo Score at Week 32 (Chronic Period) | -4.88 (-6.19 to -3.57) | -5.54 (-6.26 to -4.82) | -5.55 (-6.24 to -4.85) | -6.12 (-6.83 to -5.41) | -4.45 (-6.45 to -2.45) | -5.26 (-6.12 to -4.39) | -5.21 (-6.09 to -4.32) | -5.44 (-6.39 to -4.48) |
Collected over From the time the participants took at least 1 dose of study treatment up to 28 days after the last treatment administration. (approximately 36 Weeks). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Placebo (Induction) | 0/25 (0%) | 0/25 (0%) | 4/25 (16%) |
| PF-06651600 20 mg (Induction) | 1/51 (2%) | 3/51 (5.9%) | 8/51 (15.7%) |
| PF-06651600 70 mg (Induction) | 0/49 (0%) | 0/49 (0%) | 6/49 (12.2%) |
| PF-06651600 200 mg (Induction) | 0/50 (0%) | 3/50 (6%) | 5/50 (10%) |
| PF-06700841 10 mg (Induction) | 0/48 (0%) | 1/48 (2.1%) | 2/48 (4.2%) |
| PF-06700841 30 mg (Induction) | 0/47 (0%) | 3/47 (6.4%) | 11/47 (23.4%) |
| PF-06700841 60 mg (Induction) | 0/47 (0%) | 1/47 (2.1%) | 9/47 (19.1%) |
| PF-06651600 200 mg -> PF-06651600 50 mg | 0/35 (0%) | 3/35 (8.6%) | 9/35 (25.7%) |
| PF-06651600 70 mg -> PF-06651600 50 mg | 0/36 (0%) | 1/36 (2.8%) | 21/36 (58.3%) |
| PF-06651600 20 mg -> PF-06651600 50 mg | 0/39 (0%) | 1/39 (2.6%) | 11/39 (28.2%) |
| Placebo -> PF-06651600 50 mg | 0/10 (0%) | 0/10 (0%) | 8/10 (80%) |
| PF-06700841 60 mg -> PF-06700841 30 mg | 0/38 (0%) | 2/38 (5.3%) | 15/38 (39.5%) |
| PF-06700841 30 mg -> PF-06700841 30 mg | 0/37 (0%) | 4/37 (10.8%) | 15/37 (40.5%) |
| PF-06700841 10 mg -> PF-06700841 30 mg | 0/39 (0%) | 2/39 (5.1%) | 20/39 (51.3%) |
| Placebo -> PF-06700841 30 mg | 0/9 (0%) | 0/9 (0%) | 4/9 (44.4%) |
| Pooling Placebo During Chronic | 0/37 (0%) | 0/37 (0%) | 15/37 (40.5%) |
| Event | Placebo (Induction) | PF-06651600 20 mg (Induction) | PF-06651600 70 mg (Induction) | PF-06651600 200 mg (Induction) | PF-06700841 10 mg (Induction) | PF-06700841 30 mg (Induction) | PF-06700841 60 mg (Induction) | PF-06651600 200 mg -> PF-06651600 50 mg | PF-06651600 70 mg -> PF-06651600 50 mg | PF-06651600 20 mg -> PF-06651600 50 mg | Placebo -> PF-06651600 50 mg | PF-06700841 60 mg -> PF-06700841 30 mg | PF-06700841 30 mg -> PF-06700841 30 mg | PF-06700841 10 mg -> PF-06700841 30 mg | Placebo -> PF-06700841 30 mg | Pooling Placebo During Chronic |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Colitis ulcerativeGastrointestinal disorders | 0/25 | 1/51 | 0/49 | 1/50 | 1/48 | 0/47 | 0/47 | 0/35 | 1/36 | 1/39 | 0/10 | 1/38 | 2/37 | 1/39 | 0/9 | 0/37 |
| Ankle fractureInjury, poisoning and procedural complications | 0/25 | 0/51 | 0/49 | 0/50 | 0/48 | 0/47 | 0/47 | 1/35 | 0/36 | 0/39 | 0/10 | 0/38 | 0/37 | 0/39 | 0/9 | 0/37 |
| Femur fractureInjury, poisoning and procedural complications | 0/25 | 0/51 | 0/49 | 0/50 | 0/48 | 0/47 | 0/47 | 1/35 | 0/36 | 0/39 | 0/10 | 0/38 | 0/37 | 0/39 | 0/9 | 0/37 |
| UrticariaSkin and subcutaneous tissue disorders | 0/25 | 0/51 | 0/49 | 0/50 | 0/48 | 0/47 | 0/47 | 1/35 | 0/36 | 0/39 | 0/10 | 0/38 | 0/37 | 0/39 | 0/9 | 0/37 |
| Myocardial infarctionCardiac disorders | 0/25 | 1/51 | 0/49 | 0/50 | 0/48 | 0/47 | 0/47 | 0/35 | 0/36 | 0/39 | 0/10 | 0/38 | 1/37 | 0/39 | 0/9 | 0/37 |
| Large intestine perforationGastrointestinal disorders | 0/25 | 0/51 | 0/49 | 0/50 | 0/48 | 0/47 | 0/47 | 0/35 | 0/36 | 0/39 | 0/10 | 0/38 | 1/37 | 0/39 | 0/9 | 0/37 |
| Viral infectionInfections and infestations | 0/25 | 1/51 | 0/49 | 0/50 | 0/48 | 0/47 | 0/47 | 0/35 | 0/36 | 0/39 | 0/10 | 1/38 | 0/37 | 0/39 | 0/9 | 0/37 |
| DehydrationMetabolism and nutrition disorders | 0/25 | 0/51 | 0/49 | 0/50 | 0/48 | 0/47 | 0/47 | 0/35 | 0/36 | 0/39 | 0/10 | 1/38 | 0/37 | 0/39 | 0/9 | 0/37 |
| Acute kidney injuryRenal and urinary disorders | 0/25 | 0/51 | 0/49 | 0/50 | 0/48 | 0/47 | 0/47 | 0/35 | 0/36 | 0/39 | 0/10 | 1/38 | 0/37 | 0/39 | 0/9 | 0/37 |
| COVID-19 pneumoniaInfections and infestations | 0/25 | 0/51 | 0/49 | 0/50 | 0/48 | 0/47 | 0/47 | 0/35 | 0/36 | 0/39 | 0/10 | 0/38 | 0/37 | 1/39 | 0/9 | 0/37 |
| Event | Placebo (Induction) | PF-06651600 20 mg (Induction) | PF-06651600 70 mg (Induction) | PF-06651600 200 mg (Induction) | PF-06700841 10 mg (Induction) | PF-06700841 30 mg (Induction) | PF-06700841 60 mg (Induction) | PF-06651600 200 mg -> PF-06651600 50 mg | PF-06651600 70 mg -> PF-06651600 50 mg | PF-06651600 20 mg -> PF-06651600 50 mg | Placebo -> PF-06651600 50 mg | PF-06700841 60 mg -> PF-06700841 30 mg | PF-06700841 30 mg -> PF-06700841 30 mg | PF-06700841 10 mg -> PF-06700841 30 mg | Placebo -> PF-06700841 30 mg | Pooling Placebo During Chronic |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Colitis ulcerativeGastrointestinal disorders | 0/25 | 0/51 | 0/49 | 0/50 | 0/48 | 0/47 | 0/47 | 4/35 | 5/36 | 4/39 | 3/10 | 2/38 | 2/37 | 6/39 | 1/9 | 8/37 |
| HeadacheNervous system disorders | 2/25 | 3/51 | 3/49 | 0/50 | 1/48 | 4/47 | 0/47 | 0/35 | 0/36 | 0/39 | 2/10 | 1/38 | 1/37 | 2/39 | 0/9 | 1/37 |
| Deafness unilateralEar and labyrinth disorders | 0/25 | 0/51 | 0/49 | 0/50 | 0/48 | 0/47 | 0/47 | 0/35 | 0/36 | 1/39 | 2/10 | 0/38 | 0/37 | 0/39 | 0/9 | 0/37 |
| DiarrhoeaGastrointestinal disorders | 0/25 | 0/51 | 0/49 | 0/50 | 0/48 | 0/47 | 0/47 | 1/35 | 2/36 | 0/39 | 2/10 | 1/38 | 2/37 | 0/39 | 0/9 | 0/37 |
| OsteoarthritisMusculoskeletal and connective tissue disorders | 0/25 | 0/51 | 0/49 | 0/50 | 0/48 | 0/47 | 0/47 | 0/35 | 0/36 | 0/39 | 2/10 | 0/38 | 0/37 | 1/39 | 0/9 | 0/37 |
| HypertensionVascular disorders | 0/25 | 0/51 | 0/49 | 0/50 | 0/48 | 0/47 | 0/47 | 0/35 | 4/36 | 0/39 | 2/10 | 0/38 | 1/37 | 2/39 | 0/9 | 0/37 |
| NasopharyngitisInfections and infestations | 0/25 | 2/51 | 0/49 | 1/50 | 0/48 | 5/47 | 3/47 | 1/35 | 1/36 | 0/39 | 0/10 | 4/38 | 5/37 | 2/39 | 1/9 | 4/37 |
| AnaemiaBlood and lymphatic system disorders | 1/25 | 1/51 | 2/49 | 4/50 | 1/48 | 1/47 | 4/47 | 1/35 | 0/36 | 0/39 | 1/10 | 1/38 | 0/37 | 2/39 | 1/9 | 2/37 |
| PyrexiaGeneral disorders | 0/25 | 0/51 | 0/49 | 0/50 | 0/48 | 0/47 | 0/47 | 1/35 | 2/36 | 1/39 | 1/10 | 1/38 | 0/37 | 2/39 | 1/9 | 1/37 |
| SciaticaNervous system disorders | 0/25 | 0/51 | 0/49 | 0/50 | 0/48 | 0/47 | 0/47 | 0/35 | 0/36 | 0/39 | 0/10 | 0/38 | 0/37 | 0/39 | 1/9 | 0/37 |
All randomized participants who received at least 1 dose of PF-06651600, PF-06700841, or placebo.
| Age, Continuous(years) | Placebo (Induction) | PF-06651600 20 mg (Induction) | PF-06651600 70 mg (Induction) | PF-06651600 200 mg (Induction) | PF-06700841 10 mg (Induction) | PF-06700841 30 mg (Induction) | PF-06700841 60 mg (Induction) | Total |
|---|---|---|---|---|---|---|---|---|
| Mean | 42.8 ± 15.45 | 41.3 ± 14.03 | 40.2 ± 13.31 | 37.3 ± 15.67 | 40.8 ± 13.04 | 40.9 ± 13.03 | 40.3 ± 12.80 | 40.3 ± 13.79 |
| Age, Customized(Participants) | Placebo (Induction) | PF-06651600 20 mg (Induction) | PF-06651600 70 mg (Induction) | PF-06651600 200 mg (Induction) | PF-06700841 10 mg (Induction) | PF-06700841 30 mg (Induction) | PF-06700841 60 mg (Induction) | Total |
|---|---|---|---|---|---|---|---|---|
| 18-44 years | 13 | 31 | 30 | 36 | 31 | 25 | 30 | 196 |
| 45-64 years | 10 | 16 | 18 | 10 | 16 | 22 | 16 | 108 |
| >=65 years | 2 | 4 | 1 | 4 | 1 | 0 | 1 | 13 |
| Sex: Female, Male(Participants) | Placebo (Induction) | PF-06651600 20 mg (Induction) | PF-06651600 70 mg (Induction) | PF-06651600 200 mg (Induction) | PF-06700841 10 mg (Induction) | PF-06700841 30 mg (Induction) | PF-06700841 60 mg (Induction) | Total |
|---|---|---|---|---|---|---|---|---|
| Female | 11 | 17 | 25 | 18 | 18 | 24 | 22 | 135 |
| Male | 14 | 34 | 24 | 32 | 30 | 23 | 25 | 182 |
| Race/Ethnicity, Customized(Participants) | Placebo (Induction) | PF-06651600 20 mg (Induction) | PF-06651600 70 mg (Induction) | PF-06651600 200 mg (Induction) | PF-06700841 10 mg (Induction) | PF-06700841 30 mg (Induction) | PF-06700841 60 mg (Induction) | Total |
|---|---|---|---|---|---|---|---|---|
| White | 22 | 46 | 46 | 48 | 44 | 44 | 45 | 295 |
| Black or African American | 1 | 1 | 2 | 1 | 0 | 0 | 1 | 6 |
| Asian | 1 | 3 | 1 | 0 | 3 | 3 | 0 | 11 |
| Other (not specified) | 1 | 1 | 0 | 1 | 1 | 0 | 1 | 5 |
Showing the first 100 of 189 sites across 19 countries. Choose a country and city above to see the rest.
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.
Data sharing details ↗ · www.pfizer.com
Ran from Feb 2017 to primary completion in May 2021, 51 months.
Results were first posted in Jul 2022, 1 year 2 months after primary completion.
Of 110 industry-sponsored phase 2 interventional studies under Colitis, Ulcerative, half reached primary completion within 27 months of starting (the median), counting those still running; a quarter within 21 and three quarters within 35. This study's 51 months is above that.
Counting every sponsor, half of 154 studies reached it within 28 months; a quarter within 22 and three quarters within 43.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jun 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: PF-06700841 · PF-06651600